Cryopreservation and Hypothermal Storage of Hematopoietic Stem Cells by AlMulhem, Norah

Cryopreservation	  and	  Hypothermal	  Storage	  of	  Hematopoietic	  Stem	  Cells	  
	  	  
	  
A	  thesis	  submitted	  to	  the	  Division	  of	  Research	  and	  Advanced	  Studies	  of	  the	  University	  of	  
Cincinnati	  in	  partial	  fulfillment	  of	  the	  requirements	  for	  a	  degree	  of	  
	  
	  
MASTER	  OF	  SCIENCE	  
	  
	  
In	  the	  department	  of	  Analytical	  and	  Diagnostic	  Sciences	  of	  the	  College	  of	  Allied	  Health	  
Sciences	  and	  the	  University	  of	  Cincinnati	  Academic	  Health	  Center	  
Hoxworth	  Blood	  Center	  
By	  
	  
Norah	  A.	  Almulhem	  







Committee	  Chair:	  Thomas	  B.	  Leemhuis,	  PhD	  
	   	  
	   ii	  
	  
ABSTRACT	  
The	  recent	  availability	  of	  commercially	  available	  storage	  media	  (CryoStor™	  and	  
HypoThermosol™)	  designed	  for	  optimal	  long-­‐term	  and	  short-­‐term	  hematopoietic	  stem	  cell	  
(HSC)	  storage	  prompted	  an	  evaluation	  of	  hematopoietic	  stem	  cell	  and	  hematopoietic	  
progenitor	  cell	  (HSC/P)	  viability	  and	  functionality	  after	  storage	  in	  these	  media	  formulations,	  
compared	  with	  the	  conventional	  media	  used	  at	  Hoxworth	  Blood	  Center.	  Three	  human	  
umbilical	  cord	  blood	  units	  (CBUs)	  were	  cryopreserved	  in	  CryoStor5	  (CS5),	  CryoStor10	  (CS10),	  
and	  a	  conventional	  internally	  prepared	  cryopreservation	  medium,	  then	  analyzed	  post-­‐thaw	  
for	  viability	  and	  recovery	  of	  several	  mature	  and	  immature	  hematopoietic	  cell	  types,	  as	  well	  
as	  for	  clonogenic	  capacity,	  and	  proliferation	  potential.	  	  Flow	  cytometric	  analysis	  indicated	  
similar	  post-­‐thaw	  viability	  of	  most	  cell	  subsets	  cryopreserved	  in	  CS5,	  and	  CS10	  compared	  to	  
the	  conventional	  cryopreservation	  medium	  (containing	  5	  %	  Dimethylsulfoxide	  (DMSO)	  and	  
2.5	  %	  hydroxyethyl	  starch).	  This	  variation	  in	  viability	  was	  not	  statistically	  significant	  (p-­‐value	  
0.2-­‐1).	  Bromodeoxyuridine	  (BrdU)	  uptake	  was	  used	  to	  measure	  the	  ability	  of	  the	  
frozen/thawed	  cells	  to	  proliferate	  in	  culture	  for	  48	  h	  in	  response	  to	  stem	  cell	  factor	  (SCF),	  
FLt-­‐3	  ligand	  (FLt-­‐3)	  and	  thrombopoietin	  (TPO).	  Proliferation	  potential	  and	  clonogenic	  
capacity	  were	  both	  slightly	  better	  with	  after	  freezing	  in	  CS10;	  however,	  the	  differences	  were	  
not	  statistically	  significant.	  This	  study	  shows	  that	  the	  conventional	  medium	  for	  
cryopreservation	  used	  in	  our	  laboratory	  is	  similarly	  effective,	  compared	  with	  CS5	  or	  CS10	  
media,	  in	  protecting	  the	  cryopreserved	  CBU	  derived	  HSC/P	  products.	  
The	  same	  analytical	  methods	  were	  used	  to	  compare	  HypoThermosol®	  (HTR-­‐FRS®),	  which	  is	  
designed	  for	  short-­‐term	  refrigerated	  storage	  of	  hematopoietic	  cells,	  to	  a	  locally	  prepared	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medium	  containing	  Plasma-­‐Lyte	  A	  and	  0.5	  %	  human	  serum	  albumin	  (HSA).	  	  Measurements	  
were	  performed	  after	  24,	  48	  and	  72	  h	  of	  cold	  storage	  (4°C).	  Results	  showed	  similar	  viability	  
and	  recovery	  after	  24	  h	  of	  storage,	  but	  after	  48	  and	  72	  h,	  a	  significant	  decline	  in	  viability	  
occurred	  in	  a	  few	  of	  the	  subsets	  when	  stored	  in	  Plasma-­‐Lyte	  A/HSA	  medium,	  compared	  to	  
when	  stored	  in	  HTS-­‐FRS®.	  Differences	  in	  clonogenic	  capacity	  and	  proliferation	  potential	  
were	  not	  significant,	  however	  the	  cells’	  	  proliferation	  potential	  was	  slightly	  better	  after	  
storage	  in	  HTS-­‐FSR®.	  	  Taken	  together,	  these	  results	  indicate	  that	  the	  HTS-­‐FRS®	  storage	  
media	  preserves	  hematopoietic	  cell	  function	  better	  than	  Plasma-­‐Lyte	  A/	  0.5	  %	  HSA,	  
especially	  if	  the	  cells	  are	  to	  be	  stored	  for	  more	  than	  24	  hours.	  
It	  is	  possible	  that	  these	  in-­‐vitro	  results	  could	  translate	  to	  improved	  engraftment	  after	  
storing	  umbilical	  cord	  blood,	  bone	  marrow	  or	  mobilized	  peripheral	  blood	  in	  these	  new	  
media.	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  Modified	  Dulbecco's	  Media	  
LCP	   Lineage	  committed	  progenitors	  
MPP	   Multipotent	  progenitors	  
NC	   Nucleated	  cells	  
NMDP	   National	  Marrow	  Donor	  Program	  
PE	   Phycoerythrin	  
PrepaCyte	   PrepaCyte	  CB	  and	  PrepaCyte	  WBC	  
RT	   Room	  temperature	  
SB	   Staining	  buffer	  
SCF	   Stem	  cell	  factor	  
SSC	   Side	  scatter	  (area)	  
TM	   Thawing	  medium	  
TNC	   Total	  nucleated	  cells	  
TPO	   Thrombopoietin	  
µL	   Microliter	  
7-­‐AAD	   7-­‐Aminoactinomycin	  D	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INTRODUCTION	  
Hematopoietic	  stem	  cell	  transplantation	  
Stem	  cell	  transplantation	  is	  a	  promising	  treatment	  for	  many	  diseases.	  In	  current	  medical	  
practice,	  it	  has	  mostly	  been	  used	  as	  a	  treatment	  for	  hematological	  diseases	  to	  reconstitute	  
damaged	  bone	  marrow	  after	  aggressive	  treatment,	  such	  as	  chemotherapy	  or	  radiation	  
therapy,	  or	  to	  replace	  non-­‐functional	  marrow	  in	  bone	  marrow	  failure	  syndromes	  such	  as	  
Fanconi	  anemia.	  Hematopoietic	  stem	  and	  progenitor	  cells	  (HSC/P)	  can	  be	  harvested	  from	  
bone	  marrow	  (BM),	  cord	  blood	  and	  peripheral	  blood	  (after	  mobilization).	  	  
Human	  bone	  marrow	  transplantation	  started	  in	  1959,	  when	  professor	  Mathé	  transplanted	  
several	  patients	  after	  an	  accidental	  radiation	  exposure.	  	  	  	  This	  approach	  was	  based	  on	  a	  
previous	  finding	  that	  demonstrated	  the	  ability	  of	  bone	  marrow	  cells	  to	  reconstitute	  
damaged	  bone	  marrow.	  2	  	  The	  initial	  outcomes	  of	  BM	  transplantation	  were	  disappointing.	  In	  
1970,	  Bortin	  reported	  survival	  of	  only	  3	  out	  of	  203	  patients	  at	  2	  to	  12	  years	  period	  post	  
transplantation.	  3	  	  Dausset’s	  4	  	  and	  Van	  Rood’s	  5	  	  discovery	  of	  the	  human	  leukocyte	  antigen	  
(HLA)	  system	  opened	  doors	  for	  revolutionary	  improvements	  in	  hematopoietic	  stem	  
transplantation	  as	  it	  allowed	  selection	  of	  donors	  based	  on	  HLA	  typing,	  and	  by	  1973	  the	  first	  
unrelated	  BM	  transplant	  was	  done.	  Subsequently,	  other	  sources	  of	  HSC/P	  were	  found	  as	  the	  
first	  mobilized	  peripheral	  blood	  transplant	  was	  in	  1986	  6	  ,	  followed	  by	  the	  introduction	  of	  
cord	  blood	  (CB)	  in	  1988.	  7	  	  
The	  availability	  of	  multiple	  sources	  of	  HSC/P	  and	  the	  large	  HLA	  phenotype	  databases	  have	  
enabled	  the	  establishment	  of	  national	  and	  international	  donation	  programs,	  such	  as	  the	  
National	  Marrow	  Donor	  program	  (NMDP)	  and	  World	  Marrow	  Donor	  Association	  (WMDA).	  
These	  organizations	  help	  to	  match	  the	  HLA	  type	  of	  the	  patients	  with	  national	  or	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international	  donors.	  The	  NMDP	  data	  showed	  that	  the	  mobilized	  peripheral	  blood	  and	  CB	  
have	  started	  to	  replace	  BM	  as	  a	  source	  of	  HSC	  that	  can	  be	  used	  in	  a	  clinical	  transplant	  
practice.	  8	  	  The	  CB	  has	  a	  benefit	  over	  the	  BM	  and	  the	  mobilized	  peripheral	  blood,	  as	  it	  is	  easy	  
to	  be	  collected,	  does	  not	  require	  donor	  drug	  treatments	  prior	  to	  collection	  and	  it	  is	  readily	  
available.	  That	  makes	  it	  easier	  to	  be	  used	  in	  research	  than	  the	  earlier	  two.	  
Hematopoiesis	  and	  hematopoietic	  stem	  cell	  subsets	  
The	  hematopoietic	  stem	  cell’s	  (HSC)	  self-­‐renewal	  and	  multi-­‐lineage	  differentiation	  abilities	  
are	  the	  most	  important	  characteristics	  that	  help	  in	  the	  restoration	  of	  hematopoietic	  
function	  in	  patients	  following	  transplantation.	  Hematopoietic	  stem	  cells	  differentiate	  into	  
multipotent	  progenitors	  (MPP),	  and	  then	  to	  lineage	  committed	  progenitors	  (LCP),	  which	  will	  
give	  rise	  to	  different	  blood	  cell	  types.	  Studies	  that	  used	  single-­‐cell	  isolation	  proved	  that	  HSC	  
are	  responsible	  for	  the	  long-­‐term	  engraftment	  that	  lasts	  for	  20	  weeks	  or	  more.	  Engraftment	  
of	  MPP	  cells	  peaks	  between	  2-­‐4	  weeks	  then	  declines;	  therefore	  is	  considered	  as	  short-­‐term	  
engraftment.	  9	  	  Hematopoietic	  stem	  cells,	  progenitor	  and	  mature	  cells	  express	  different	  
surface	  antigens	  that	  vary	  in	  nature	  and	  function.	  Flow	  cytometric	  analysis	  using	  specific	  
fluorescent-­‐labeled	  monoclonal	  antibodies	  against	  these	  surface	  antigens	  allows	  the	  
quantification	  of	  various	  cell	  subsets	  (Figure	  1).	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Figure	  1:	  Hematopoiesis.	  10	  
	  
In	  addition	  to	  cell	  surface	  antigens,	  the	  stem	  cell	  can	  be	  defined	  by	  biological	  characteristics	  
such	  as	  its	  enzyme	  content.	  Stem	  cells	  contain	  higher	  levels	  of	  the	  enzyme	  aldehyde	  
dehydrogenase	  (ALDH)	  than	  more	  mature	  cells	  ,	  thus	  ALDH	  content	  can	  be	  used	  to	  measure	  
stem	  cell	  content.	  11	  
In	  current	  clinical	  practice,	  the	  number	  of	  CD45+/CD34+	  cells	  in	  the	  graft	  is	  used	  to	  
determine	  the	  number	  of	  progenitor	  cells,	  and	  to	  calculate	  the	  cell	  dose	  available	  for	  
transplantation.	  The	  CD34+	  population	  is	  a	  heterogeneous	  population	  that	  is	  composed	  of	  
multiple	  cell	  types	  that	  vary	  in	  stages	  of	  maturity	  and	  ability	  to	  proliferate	  and/or	  
differentiate	  into	  various	  hematopoietic	  lineages.	  This	  heterogeneous	  cell	  population	  can	  
either	  lose	  or	  gain	  the	  expression	  of	  surface	  antigens	  such	  as	  CD38	  and	  CD90	  along	  with	  
differentiation.	  The	  most	  immature	  (stem	  cell-­‐like)	  cell	  subset	  within	  the	  CD34+	  population	  
is	  the	  enriched	  HSC,	  which	  is	  CD34+,	  CD38-­‐	  and	  CD90+	  (abbreviated	  CD90+).	  As	  the	  CD90+	  
cells	  undergo	  differentiation,	  they	  lose	  CD90	  expression,	  but	  are	  still	  capable	  of	  multilineage	  
differentiation,	  and	  are	  thus	  called	  multipotent	  progenitor	  cells	  (MPP)	  (abbreviated	  CD90-­‐).	  
With	  continued	  differentiation,	  the	  MPP	  begin	  to	  become	  more	  lineage	  restricted	  and	  start	  
to	  express	  the	  CD38	  antigen,	  thus	  are	  named	  lineage	  committed	  progenitors	  (LCP)	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(abbreviated	  CD38+).	  These	  progenitor	  cell	  populations	  are	  responsible	  for	  the	  early	  and	  
late	  engraftment	  activities	  of	  the	  transplanted	  graft.	  There	  are	  other	  cell	  surface	  antigens	  
that	  have	  been	  used	  to	  enrich	  for	  the	  HSC,	  as	  previous	  studies	  proved	  that	  approximately	  1	  
in	  5.5	  HSC	  lack	  CD90	  expression.	  9	  	  Those	  studies	  used	  single	  cell	  isolation	  using	  flow	  
cytometry	  sorting	  to	  identify	  the	  engraftment	  capability	  of	  each	  cell	  subset.	  However,	  this	  
study	  utilized	  a	  CD34+	  CD38-­‐	  CD90+	  definition	  of	  an	  HSC	  when	  assessing	  HSC	  viability	  before	  
and	  after	  storage.	  	  
In	  addition	  to	  progenitor	  cells,	  the	  transplanted	  graft	  contains	  a	  mixture	  of	  mature	  WBC	  
(CD45+)	  that	  are	  not	  responsible	  for	  engraftment,	  but	  are	  important	  in	  other	  ways.	  The	  
mature	  population	  includes	  T-­‐cells,	  which	  are	  important	  for	  some	  clinical	  practices	  as	  donor	  
lymphocyte	  infusions	  (DLI)	  to	  combat	  graft	  rejection	  post-­‐transplant.	  Thus,	  it	  is	  important	  to	  
know	  whether	  progenitor	  cells	  and	  mature	  cells	  survive	  cryopreservation	  and	  storage.	  
	  
Cryopreservation	  history	  
Cell	  storage	  conditions	  designed	  to	  allow	  cell	  survival	  after	  storage	  were	  studied	  early	  in	  the	  
18th	  century,	  when	  Reaumur	  12	  	  and	  Spallanzani	  13	  	  described	  the	  effects	  of	  cold	  temperature	  
storage	  on	  cell	  viability.	  By	  1949,	  Polge,	  Smith,	  and	  Parkers	  demonstrated	  the	  revival	  of	  bull	  
spermatozoa	  after	  storage	  at	  low	  temperatures	  and	  discovered	  the	  first	  cryoprotective	  
agent	  (CPA),	  glycerol.	  14	  	  This	  protocol	  was	  applied	  to	  human	  sperm	  cells,	  in	  1953,	  by	  
Sherman	  et	  al,	  who	  established	  the	  first	  sperm	  bank.	  13	  Later,	  in	  1955,	  Barnes	  and	  Loutit	  
started	  the	  cryopreservation	  of	  HSC	  using	  glycerol.	  15	  In	  1959,	  Lovelock	  and	  Bishop	  
introduced	  dimethylsulfoxide	  (DMSO)	  as	  a	  CPA	  and	  compared	  it	  with	  glycerol	  using	  the	  
extent	  of	  hemolysis	  of	  red	  blood	  cells	  as	  a	  measure	  of	  cell	  damage	  caused	  by	  freezing.	  16	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There	  are	  two	  kinds	  of	  cryoprotective	  agents	  (CPAs),	  those	  that	  are	  membrane	  permeable	  
(e.g.	  glycerol	  and	  DMSO),	  and	  those	  that	  are	  non-­‐permeable	  (e.g.	  Dextran	  and	  Hydroxyethyl	  
starch	  (HES)).	  Permeable	  CPAs	  are	  characterized	  by	  having	  a	  low	  molecular	  weight,	  high	  
solubility	  in	  aqueous	  electrolyte	  solutions,	  and	  the	  ability	  to	  permeate	  living	  cells,	  while	  
non-­‐permeable	  CPAs	  have	  a	  high	  molecular	  weight,	  which	  stabilizes	  the	  cell	  membrane	  of	  
the	  frozen	  cells.	  Non-­‐permeable	  CPAs	  augment	  the	  effectiveness	  of	  the	  membrane	  
permeable	  CPAs	  and	  allow	  the	  use	  of	  lower	  concentrations	  of	  membrane	  permeable	  CPA.	  
Together,	  the	  CPAs	  help	  to	  prevent	  cell	  injury	  caused	  by	  the	  formation	  of	  intra-­‐	  and	  extra-­‐
cellular	  ice	  crystals,	  and	  also	  help	  control	  the	  rate	  of	  water	  transport	  into	  and	  out	  of	  the	  cell	  
during	  freezing,	  which	  decreases	  the	  toxic	  effect	  of	  hypertonic	  concentrations	  of	  
electrolytes	  and	  other	  substances	  that	  occurs	  as	  cells	  freeze.	  The	  benefit	  of	  DMSO	  over	  
other	  CPAs	  is	  having	  a	  greater	  permeability	  in	  living	  cells.	  Five	  to	  ten	  percent	  DMSO	  is	  the	  
most	  commonly	  used	  cryoprotective	  agent.	  17	  	  
A	  slow,	  gradual	  addition	  of	  DMSO	  is	  used	  to	  protect	  cells	  from	  damage	  caused	  by	  osmotic	  
stress	  and	  the	  exothermic	  reaction	  that	  occurs	  as	  the	  concentrated	  DMSO	  solution	  mixes	  
with	  the	  cell	  solution.	  
Lionetti	  first	  introduced	  the	  use	  of	  DMSO	  and	  HES	  in	  the	  cryopreservation	  media	  for	  
granulocyte	  cryopreservation	  in	  1975.	  18	  In	  1980	  he	  found	  that	  adding	  human	  albumin	  to	  the	  
cryopreservation	  medium	  acts	  as	  a	  cell	  membrane	  stabilizer.	  19	  	  Stiff	  and	  colleagues	  
introduced	  cryopreservation	  of	  bone	  marrow	  using	  DMSO,	  HES	  and	  human	  albumin	  in	  1987.	  
20	  Additional	  studies	  performed	  in	  1991,	  by	  Makino	  and	  associates	  to	  determine	  the	  optimal	  
concentrations	  of	  DMSO	  for	  stem	  cells	  cryopreservation	  media,	  found	  that	  5%	  DMSO	  and	  
6%	  HES	  were	  optimal.	  21	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Cryopreservation	  protocols	  for	  HSC	  have	  remained	  relatively	  unchanged	  since	  the	  first	  cord	  
blood-­‐banking	  program	  commenced	  in	  1992.	  22	  	  New	  approaches	  and	  methods	  for	  
cryopreservation	  are	  needed	  to:	  decrease	  preparation	  and	  processing	  time,	  improve	  post-­‐
thaw	  recovery	  and	  viability,	  and	  reduce	  DMSO	  toxicity.	  	  Improvements	  in	  the	  materials	  (or	  
methods)	  used	  to	  cryopreserve	  HSC/P	  products	  that	  result	  in	  better	  post-­‐thaw	  viability	  and	  
recovery	  may	  enhance	  the	  engraftment	  of	  transplanted	  HSC/P	  products.	  In	  the	  current	  
practice,	  cryopreservation	  media	  are	  not	  standardized	  between	  	  centers.	  Generally,	  it	  is	  
composed	  of	  5	  or	  10%	  DMSO,	  balanced	  salt	  solutions	  (e.g.	  Normosol-­‐R	  or	  Plasma-­‐Lyte	  A),	  an	  
anticoagulant	  (anticoagulant	  citrate	  dextrose	  (ACD-­‐A))	  and	  a	  protein	  source	  such	  as	  human	  
plasma	  or	  human	  albumin.	  Commercially	  available	  cryopreservation	  and	  hypothermal	  
storage	  media	  will	  help	  in	  standardizing	  the	  cryopreservation	  and	  transportation	  procedures	  
among	  stem	  cell	  processing	  centers	  worldwide.	  
Transport	  media	  	  
The	  availability	  of	  international	  HSC	  donation	  programs	  increases	  the	  demand	  for	  better	  
quality	  transport	  media.	  The	  National	  Marrow	  Donor	  Program	  (NMDP)	  outcome	  data	  
showed	  that	  more	  than	  6,200	  allogeneic	  transplants	  occurred	  in	  2011	  and	  more	  than	  6,700	  
in	  2012.	  Also,	  demand	  for	  allogeneic	  transplants	  is	  increasing	  by	  nine	  percent	  annually.	  8	  
Cells	  are	  exposed	  to	  numerous	  physical	  and	  chemical	  stresses	  during	  transport	  that	  can	  
result	  in	  changes	  in	  membrane-­‐mediated	  ion	  transport	  and	  intracellular	  acidosis	  (pH=4)	  23-­‐24	  
and	  ultimately,	  loss	  of	  viability.	  Transport	  media	  are	  used	  to	  protect	  the	  cells	  from	  these	  
stresses	  as	  it	  maintains	  the	  ion	  balance,	  works	  as	  a	  free	  radical	  scavenger,	  provides	  osmotic	  
support	  and	  nutrients,	  and	  controls	  stress	  pathways	  that	  are	  activated	  by	  hypothermal	  
storage.	  	  Improving	  the	  transport	  media	  could	  result	  in	  decreased	  cell	  injury	  caused	  by	  delay	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in	  transporting	  an	  allogeneic	  graft.	  It	  could	  also	  ease	  cellular	  therapy	  laboratory	  operations,	  
as	  it	  would	  be	  possible	  to	  delay	  product	  processing	  and	  allow	  for	  overnight	  storage	  and	  
pooling	  of	  two	  consecutive	  peripheral	  blood	  stem	  cell	  products.	  Previous	  studies	  performed	  
to	  determine	  the	  stability	  of	  HSC	  products	  in	  transport	  media	  during	  overnight	  storage	  at	  
4°C	  prior	  to	  cryopreservation	  have	  shown	  that	  overnight	  storage	  has	  no	  deleterious	  impact	  
on	  short-­‐	  or	  long-­‐term	  engraftment	  	  25	  ,	  however	  improving	  the	  quality	  of	  the	  transport	  
media	  might	  allow	  products	  to	  remain	  viable	  for	  an	  even	  longer	  period	  of	  time	  in	  instances	  
of	  transport	  delays	  and	  might	  someday	  allow	  transfusion	  of	  fresh	  autologous	  products.	  This	  
would	  reduce	  patient	  exposure	  to	  cryoprotectants,	  which	  have	  an	  associated	  toxicity	  risk,	  
and	  decrease	  serious	  adverse	  reactions	  after	  infusion	  of	  cryopreserved	  products.	  26	  
Previous	  studies	  comparing	  different	  transport	  media	  showed	  that	  hypothermic	  storage	  
using	  HypoThermosol-­‐FRS®	  (HTS-­‐FRS®)	  for	  2	  and	  4	  days	  results	  in	  approximately	  100	  %	  and	  
85	  %	  stromal	  cell	  recovery,	  respectively.	  27	  
Two	  additional	  studies	  have	  shown	  that	  the	  use	  of	  HTS-­‐FRS®	  results	  in	  improved	  viability	  
and	  metabolic	  activity	  of	  the	  transported	  and	  stored	  cells	  and	  tissues	  when	  compared	  with	  
other	  media.	  28-­‐29	  	  	  	  
HYPOTHESIS	  
Commercially	  available	  storage	  media	  (CryoStor®	  and	  HTS-­‐FRS®)	  designed	  specifically	  for	  
cryopreservation	  and	  hypothermal	  storage	  will	  improve	  the	  viability	  and	  functionality	  of	  
HSC/P	  subsets	  compared	  to	  conventional	  cryopreservation	  and	  hypothermal	  storage	  media.	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Specific	  aims	  	  
Aim1:	  To	  determine	  the	  effect	  of	  different	  cryopreservation	  media	  on	  post	  thaw	  viability,	  
recovery	  and	  functionality	  of	  recovered	  cell	  subsets.	  
For	  this	  aim,	  post	  thaw	  samples	  were	  obtained	  from	  cord	  blood	  units	  (CBU)	  that	  were	  
cryopreserved	  using	  CS5®,	  CS10®	  or	  conventional	  media.	  Samples	  were	  analyzed	  for	  viability,	  
recovery	  and	  functionality	  of	  hematopoietic	  stem	  and	  progenitor	  cell	  subsets.	  In-­‐vitro	  
progenitor	  cell	  function	  assays	  were	  utilized	  to	  test	  the	  cells’	  ability	  to	  form	  colonies	  and	  to	  
proliferate	  in	  culture.	  	  A	  colony-­‐forming	  unit	  (CFU)	  assay	  was	  used	  to	  determine	  
proliferative	  potential	  of	  committed	  hematopoietic	  progenitor	  cells,	  whereas	  the	  cells’	  
ability	  to	  proliferate	  in	  media	  in	  response	  to	  a	  cytokine	  combination	  (stem	  cell	  factor	  (SCF),	  
Flt3-­‐ligand	  and	  thrombopoietin	  (TPO))	  intended	  to	  induce	  the	  proliferation	  of	  HSCs	  and	  
immature	  progenitors,	  but	  not	  committed	  progenitors,	  was	  used	  to	  measure	  stem	  cell	  
function.	  	  
Aim2:	  To	  determine	  the	  effect	  of	  using	  different	  transport	  media	  on	  protecting	  viable	  cells	  
during	  transportation	  and	  hypothermic	  storage	  of	  HSC	  products.	  	  
For	  this	  aim,	  CBU	  were	  processed	  and	  stored	  at	  4-­‐6°C	  in	  either	  HTS-­‐FRS®	  or	  conventional	  
Plasma-­‐Lyte	  A/0.5	  %	  HSA	  medium.	  Samples	  were	  tested	  after	  refrigerated	  storage	  for	  24,	  48	  
and	  72	  h	  for	  viability,	  recovery	  of	  viable	  cells,	  and	  functionality	  in	  the	  same	  manner	  as	  for	  
aim	  1	  above.	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RESEARCH	  PLAN/OBJECTIVES	  
The	  project	  had	  two	  objectives:	  
1.	  ,	  Analysis	  of	  performance	  of	  different	  cryopreservation	  media	  for	  UCB	  HSC/P.	  
2.	  Analysis	  of	  CBU	  stored	  at	  a	  refrigerated	  temperature	  in	  different	  transport	  solutions.	  	  	  
For	  each	  of	  them,	  the	  recovery	  and	  viability	  of	  total	  nucleated	  cells	  (TNC),	  viability	  and	  
recovery	  of	  mature	  and	  immature	  cell	  subsets,	  clonogenic	  capacity	  and	  proliferation	  
potential	  were	  measured	  after	  storage	  to	  determine	  whether	  using	  a	  commercially	  available	  
cryopreservation	  (CryoStor®)	  and	  transport	  (HypoThermosol®)	  media	  improves	  post	  storage	  
viability,	  recovery	  and	  functionality.	  	  
The	  research	  plan	  is	  outlined	  in	  Figure	  2.	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Figure	  2:	  Illustration	  of	  the	  research	  plan.	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MATERIALS	  
Umbilical	  cord	  blood	  units	  (CBU)	  
Six	  CBU	  were	  used	  as	  a	  representative	  source	  of	  HSC	  for	  analysis.	  The	  CBU	  were	  obtained	  
from	  deliveries	  at	  Christ	  Hospital	  through	  Cincinnati	  Children’s	  Hospital-­‐Translational	  Core	  
Laboratories	  Cell	  Processing	  Core	  through	  an	  IRB-­‐approved	  volunteer	  donation	  protocol	  
that	  allows	  investigators	  to	  request	  and	  receive	  CBU	  anonymously	  (CCHMC	  IRB	  approval	  #	  
00002988).	  	  Units	  were	  eligible	  for	  the	  study	  if	  they	  were	  collected	  within	  24	  h	  before	  
processing;	  CBU	  had	  TNC	  count	  ≥	  300	  x	  106	  with	  at	  least	  90	  %	  viability.	  
PrepaCyte®	  
A	  commercially	  available	  kit	  containing	  PrepaCyte®	  (PrepaCyte®	  BioE,	  St.	  Paul,	  MN)	  was	  
used	  to	  RBC	  reduce	  CBU	  prior	  to	  storage.	  PrepaCyte®	  is	  a	  non-­‐density	  based	  buffer	  that	  
enables	  rapid	  and	  efficient	  removal	  of	  red	  blood	  cells	  (RBC)	  by	  aggregating	  and	  sedimenting	  
RBC.	  	  It	  	  allows	  the	  recovery	  of	  the	  white	  blood	  cells	  (WBC)(Figure	  3).	  30	  	  
	  
Figure	  3:	  PrepaCyte®CB	  bag	  set	  schematic.	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Conventional	  cryopreservation	  medium	  
The	  conventional	  cryopreservation	  medium	  is	  composed	  of	  5	  %	  DMSO	  (Stemsol™,	  Protide	  
Pharmaceutical	  Inc.,	  Lake	  Zurich,	  IL),	  2.5	  %	  hydroxyethyl	  starch	  (HES,	  6	  %	  hetastarch	  in	  0.9	  %	  
sodium	  chloride,	  Hospira,	  Lake	  Forest,	  IL),	  10	  %	  ACD-­‐A	  (acid	  citrate	  dextrose,	  solution	  A,	  
CaridianBCT,	  Lakewood,	  CO),	  10	  %	  human	  serum	  albumin	  (HSA),	  (Catalog	  #	  2G0201	  25	  %	  
solution,	  Baxter	  Healthcare	  Corporation,	  Deerfield,	  IL)	  and	  Plasma-­‐Lyte	  A	  (Baxter	  Healthcare	  
Corporation,	  Deerfield,	  IL).	  	  
Plasma-­‐Lyte	  A	  is	  an	  electrolyte	  solution	  similar	  in	  composition	  to	  the	  extracellular	  fluid.	  It	  
contains	  sodium,	  potassium,	  magnesium,	  chloride,	  acetate,	  sodium	  chloride,	  sodium	  
gluconate,	  sodium	  acetate	  trihydrate,	  potassium	  chloride,	  magnesium	  chloride	  and	  
gluconate.	  It	  has	  a	  pH	  of	  7.4	  and	  an	  osmolality	  of	  294	  mOsm/L.	  ACD-­‐A	  consists	  of	  dextrose	  
monohydrate,	  sodium	  citrate	  dihydrate	  and	  citric	  acid	  anhydrous	  in	  water	  for	  Injection.	  
CryoStor®	  
CryoStor	  is	  a	  commercially	  available,	  animal	  protein	  free,	  and	  serum	  free	  cryopreservation	  
medium	  (BioLife	  Solutions)	  designed	  to	  prepare	  and	  preserve	  cells	  in	  ultra-­‐low	  temperature	  
environments	  (-­‐80°C	  to	  -­‐196°C);	  CryoStor	  is	  composed	  of	  dextran-­‐40,	  sodium,	  potassium,	  
calcium,	  magnesium,	  phosphate,	  4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  
(HEPES),	  lactobionate,	  sucrose,	  mannitol,	  glucose,	  adenosine	  and	  glutathione.	  It	  has	  a	  pH	  of	  
7.6	  and	  an	  osmolality	  of	  360	  mOsm/kg	  H2O.	  31	  It	  was	  engineered	  to	  maintain	  a	  cell’s	  osmotic	  
balance	  under	  low	  temperature	  conditions,	  thereby	  reducing	  osmotic	  gradients,	  which	  lead	  
to	  the	  onset	  of	  cell	  death	  via	  apoptosis,	  necrosis,	  and	  secondary	  necrosis.	  17	  CryoStor®	  is	  pre-­‐
formulated	  with	  different	  concentrations	  of	  DMSO.	  In	  this	  study,	  CryoStor	  media	  with	  5	  and	  
10	  %	  DMSO	  (CS5	  and	  CS10)	  were	  used.	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Thawing	  medium	  
A	  thawing	  media	  (TM)	  consisting	  of	  30	  %	  Plasma-­‐Lyte	  A,	  6	  %	  dextran,	  2.5	  %	  HSA	  and	  10	  
U/mL	  of	  heparin	  (Hospira)	  was	  prepared	  and	  chilled	  at	  4-­‐6°C	  for	  at	  least	  20	  min	  prior	  to	  use.	  
Conventional	  hypothermal-­‐storage	  medium	  
A	  conventional	  hypothermal	  storage	  (transport)	  medium	  was	  used,	  consisting	  of	  Plasma-­‐
Lyte	  and	  0.5	  %	  HSA	  (25	  %	  solution)	  (both	  Baxter	  Healthcare).	  	  
HypoThermosol®	  
HypoThermosol-­‐FRS®	  (HTR-­‐FRS®,	  BioLife	  Solutions)	  is	  a	  commercially	  available	  transport	  
medium	  that	  is	  composed	  of	  dextran-­‐40,	  sodium	  chloride,	  potassium	  chloride,	  calcium	  
chloride,	  magnesium	  chloride,	  dihydrogen	  phosphate,	  bicarbonate,	  HEPES,	  lactobionate,	  
sucrose,	  mannitol,	  glucose,	  adenosine	  and	  glutathione.	  It	  has	  a	  pH	  of	  7.6	  and	  an	  osmolality	  
of	  360	  mOsm/kg	  H2O.	  29	  
METHODS	  
All	  procedures	  that	  involve	  an	  open	  system	  were	  performed	  aseptically	  under	  a	  class	  II	  
biological	  safety	  cabinet	  (BSC,	  SteriGard	  Hood	  type	  A/B3,	  Baker	  Co.	  Inc.,	  Sanford,	  Maine).	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Cord	  blood	  processing	  
Upon	  receipt	  of	  a	  CBU,	  a	  0.4	  mL	  sample	  was	  collected	  through	  a	  blood	  bag	  spike	  adaptor	  
(catalog	  #	  1C8687,	  Baxter	  Healthcare)	  to	  determine	  the	  TNC	  count	  (automated	  cell	  counter,	  
COULTER	  AC.T	  5	  diff	  CP,	  BECKMAN	  COULTER,	  Brea,	  CA)	  and	  the	  viability	  (flow	  cytometry,	  
FACSCanto	  II,	  BD	  Biosciences,	  San	  Jose,	  CA).	  	  
RBC	  depletion	  was	  performed	  using	  a	  commercially	  available	  kit	  (contains	  PrepaCyte®	  
buffer).	  The	  manufacturer’s	  recommended	  protocol	  was	  followed.	  
If	  the	  minimum	  criteria	  were	  met	  (cell	  count	  and	  viable	  TNC	  percentage),	  the	  CBU	  was	  
transferred	  to	  processing	  bag	  number	  1	  that	  contained	  the	  PrepaCyte	  solution	  using	  an	  
attached	  spike.	  For	  optimal	  recovery,	  a	  portion	  of	  the	  reagent–cord	  blood	  mixture—was	  
drained	  back	  into	  the	  collection	  bag,	  mixed	  and	  transferred	  back	  into	  bag	  number	  1.	  The	  
primary	  collection	  bag	  was	  then	  rinsed	  with	  5	  mL	  of	  Plasma-­‐Lyte	  A	  solution.	  The	  tubing	  
between	  the	  primary	  collection	  bag	  and	  processing	  bag	  number	  1	  was	  heat-­‐sealed	  and	  the	  
primary	  collection	  bag	  was	  discarded.	  The	  reagent-­‐cord	  blood	  mixture	  was	  mixed	  manually	  
for	  15-­‐20	  min.	  After	  mixing,	  the	  bag	  set	  was	  suspended	  on	  a	  manual	  plasma	  expressor	  
(Fenwal	  Laboratories,	  Deerfield,	  IL)	  for	  45-­‐60	  min.	  The	  TNC	  rich	  supernatant	  was	  then	  
transferred	  slowly	  to	  bag	  number	  2	  using	  the	  plasma	  expressor	  and	  a	  hemostat	  to	  control	  
the	  flow	  rate.	  The	  second	  bag	  along	  with	  its	  contents	  was	  centrifuged	  at	  400	  x	  g	  for	  10	  min.	  
(Beckman	  GS-­‐6R	  centrifuge,	  BECKMAN	  COULTER	  Inc.)	  with	  the	  brake	  off	  to	  avoid	  disruption	  
of	  the	  pellet.	  Once	  more	  using	  the	  plasma	  expressor,	  the	  second	  unwanted	  supernatant	  was	  
transferred	  back	  to	  bag	  number	  1.	  The	  final	  product	  volume	  was	  measured	  by	  transferring	  it	  
aseptically	  through	  the	  kit	  port	  to	  a	  30	  mL	  syringe	  (Catalog	  #	  309650,	  BD,	  Franklin	  Lakes,	  NJ).	  
The	  RBC-­‐depleted	  product	  was	  then	  returned	  to	  bag	  number	  2.	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After	  the	  CBU	  had	  been	  processed,	  samples	  were	  taken	  for	  cell	  counts,	  flow	  cytometry	  
(subsets	  viability	  and	  recovery	  analyses),	  clonogenic	  capacity,	  and	  proliferation	  potential	  
before	  cryopreserving	  (freezing)	  or	  hypothermal	  storage	  at	  4oC.	  	  
Cryopreservation	  	  
Three	  of	  the	  RBC-­‐depleted	  CBU	  were	  cryopreserved	  in	  cryovials.	  Six	  5	  mL	  cryovials	  (Catalog	  
#	  CLS430663,	  Corning	  Inc.,	  Corning,	  NY)	  were	  prepared;	  labeled	  A1,	  A2,	  B1,	  B2,	  C1	  and	  C2.	  
Each	  set	  of	  two	  was	  cryopreserved	  using	  different	  media.	  Vials	  A1	  and	  A2	  were	  processed	  
with	  the	  conventional	  media,	  B1	  and	  B2	  with	  CS5	  and	  C1	  and	  C2	  with	  CS10.	  Equal	  volumes	  
of	  the	  final	  product	  were	  transferred	  to	  each	  vial.	  The	  cryopreservation	  volume	  was	  reduced	  
by	  centrifuging	  the	  vials	  for	  10	  min.	  at	  200	  x	  g.	  The	  supernatant	  was	  then	  aspirated	  using	  a	  5	  
mL	  graduated	  pipette	  (Corning	  Inc.)	  and	  each	  vial	  processed	  with	  the	  corresponding	  
cryopreservation	  media	  to	  a	  final	  concentration	  of	  5-­‐50	  X	  106	  NC/mL	  per	  3	  mL	  
cryopreserved	  product.	  	  
After	  adding	  the	  cryopreservation	  media,	  vials	  were	  stored	  overnight	  in	  a	  -­‐70°C	  freezer	  in	  a	  
freezing	  container	  that	  provides	  a	  repeatable	  -­‐1°C/min	  cooling	  rate	  (Mr.	  Frosty,	  Thermo	  
Fisher	  Nalgene,	  Waltham,	  MA)	  before	  transferring	  to	  liquid	  nitrogen	  storage	  (vapor	  phase).	  
After	  at	  least	  24	  hrs	  in	  liquid	  nitrogen,	  one	  set	  of	  the	  cryopreserved	  tubes	  (A1,	  B1	  and	  C1)	  
was	  thawed,	  washed,	  and	  diluted	  prior	  to	  testing,	  and	  the	  second	  set	  of	  tubes	  was	  left	  as	  a	  
backup.	  
For	  the	  conventional	  cryopreservation	  process,	  cryopreservation	  medium	  containing	  DMSO	  
and	  HES	  (300µL	  and	  900µL	  respectively)	  was	  prepared	  and	  pre-­‐chilled	  at	  4-­‐6°C	  for	  at	  least	  
15	  min.	  before	  adding	  it	  to	  the	  cell	  suspension.	  Cell	  pellets	  were	  re-­‐suspended	  with	  500	  µL	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Plasma-­‐Lyte,	  300	  µL	  25	  %	  HSA,	  800	  µL	  6	  %	  HES	  and	  300	  µL	  ACD-­‐A	  and	  then	  chilled	  for	  10	  min.	  
at	  4-­‐6°C.	  After	  chilling,	  600	  µL	  of	  the	  pre-­‐cooled	  cryopreservation	  media	  were	  slowly	  added	  
to	  the	  cell	  suspension.	  The	  cryovials	  were	  then	  placed	  in	  a	  5	  mL	  Mr.	  Frosty	  container	  and	  
immediately	  placed	  in	  a	  -­‐70°C	  freezer.	  
For	  B1	  and	  C1,	  vials	  designated	  for	  CS5	  and	  CS10,	  cell	  pellets	  were	  re-­‐suspended	  with	  2.5	  mL	  
of	  pre-­‐chilled	  CS5®	  or	  CS10®	  (at	  4-­‐6°C)	  to	  reach	  a	  final	  volume	  of	  3	  mL.	  The	  vials	  were	  then	  
placed	  in	  a	  5	  mL	  Mr.	  Frosty	  and	  further	  chilled	  for	  10	  min.	  at	  4-­‐6°C.	  then	  placed	  in	  a	  -­‐70°C	  
freezer.	  
Thawing	  procedure	  
The	  cryopreserved	  vials	  were	  thawed	  after	  a	  minimum	  of	  24	  h	  in	  vapor	  phase	  liquid	  
nitrogen	  storage.	  Immediately	  after	  thawing,	  cryovials	  were	  diluted	  1:12	  with	  cold	  TM	  in	  
order	  to	  avoid	  drastic	  changes	  in	  osmolality	  and	  prevent	  toxicity	  from	  the	  DMSO.	  	  
The	  cryovials	  were	  always	  handled	  in	  parallel	  and	  the	  thawing	  procedure	  was	  standardized	  
for	  all	  of	  the	  cryopreserved	  samples.	  The	  samples	  were	  removed	  from	  a	  liquid	  nitrogen	  
freezer,	  then	  thawed	  in	  a	  37°C	  water	  bath	  with	  gentle	  swirling,	  until	  all	  visible	  ice	  was	  
melted.	  Vials	  were	  then	  immediately	  placed	  under	  a	  BSC	  to	  be	  diluted	  with	  the	  precooled	  
TM.	  One	  mL	  of	  the	  TM	  was	  added	  drop	  wise	  to	  minimize	  osmotic	  shock	  to	  the	  cryovials,	  and	  
then	  its	  entire	  content	  transferred	  to	  a	  50	  mL	  labeled	  sterile	  centrifuge	  tube	  (catalog	  #	  
C1062-­‐P,	  Denville	  Scientific	  Inc.,	  South	  Plainfield,	  NJ).	  The	  cryovials	  were	  rinsed	  with	  1	  mL	  of	  
the	  TM	  and	  31	  mL	  of	  the	  TM	  was	  added	  slowly	  (drop	  wise)	  to	  the	  50	  mL	  centrifuge	  tube.	  	  
Immediately	  after	  the	  addition	  of	  TM,	  0.4	  mL	  post-­‐thaw	  samples	  were	  taken	  for	  automated	  
cell	  count	  and	  flow	  cytometry	  testing.	  The	  diluted	  post-­‐thaw	  samples	  were	  then	  incubated	  
for	  30	  min.	  at	  RT.	  These	  were	  then	  centrifuged	  at	  200	  x	  g	  for	  10	  min.	  The	  supernatant	  was	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discarded	  and	  the	  cell	  pellet	  re-­‐suspended	  with	  5	  mL	  of	  the	  TM.	  The	  TNC	  count	  was	  
calculated	  and	  samples	  for	  CFU	  and	  proliferation	  assay	  were	  taken.	  
Hypothermal	  storage.	  
Three	  CBU	  were	  processed	  for	  hypothermal	  storage.	  After	  calculating	  the	  TNC,	  the	  post-­‐
processing	  product	  volume	  was	  divided	  equally	  into	  two	  50	  mL	  centrifuge	  tubes	  A	  and	  B.	  
The	  tubes	  were	  centrifuged	  at	  300	  x	  g	  for	  10	  min.	  to	  reduce	  the	  volume.	  The	  volume	  of	  
hypothermal	  storage	  media	  was	  calculated	  to	  obtain	  a	  final	  concentration	  of	  50	  X	  106	  
NC/mL.	  Each	  cell	  pellet	  was	  re-­‐suspended	  with	  the	  corresponding	  storage	  media	  and	  mixed	  
well.	  The	  tube	  content	  was	  transferred	  into	  two	  150	  mL	  transfer	  bags	  (catalog	  #	  4R2011,	  
Baxter).	  Bags	  were	  then	  stored	  in	  a	  monitored	  4-­‐6°C	  refrigerator.	  Samples	  were	  obtained	  
periodically	  after	  24,	  48	  and	  72	  h	  in	  order	  to	  evaluate	  different	  storage	  conditions.	  	  
	  
Flow	  cytometry	  
Flow	  cytometry	  utilizes	  monoclonal	  antibodies	  conjugated	  with	  fluorochromes,	  which	  bind	  
to	  the	  targeted	  antigens	  and	  emit	  florescence	  at	  different	  wavelengths	  when	  passed	  
through	  a	  laser	  beam.	  A	  flow	  cytometer	  was	  used	  for	  cell	  subset	  identification,	  viability	  
measurement,	  ALDH	  quantitation	  (ALDEFLUOR	  assay),	  and	  BrdU	  incorporation.	  
To	  evaluate	  the	  various	  cell	  subsets,	  pre	  and	  post	  storage	  samples	  were	  stained	  with	  
fluorochrome-­‐conjugated	  antibodies	  against	  different	  surface	  antigens	  (anti-­‐CD45-­‐PE	  
(Phycoerythrin),	  anti-­‐CD34-­‐APC-­‐Cy7	  (Allophycocyanin	  with	  cyanin-­‐7),	  anti-­‐CD38-­‐APC	  
(Allophycocyanin),	  anti-­‐CD90-­‐PE,	  anti-­‐CD3-­‐APC	  (Table	  1)	  in	  different	  combinations.	  	  Viability	  
was	  measured	  using	  7-­‐AAD	  (BD	  Pharmingen,	  San	  Jose,	  CA)	  and	  annexin-­‐V-­‐FITC	  (Fluorescein	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isothiocyanate).	  	  The	  ALDEFLUOR	  assay	  (STEMCELL	  Technologies,	  Vancouver,	  BC,	  Canada)	  
was	  utilized	  to	  measure	  ALDH	  content.	  
Table	  1:	  List	  of	  antibodies	  against	  HSC/P	  subsets	  surface	  antigens	  used	  for	  flow	  cytometry.	  
Product	  Name	   Fluorochrome	   Clone	   Producer	  
CD45	   PE	   TU116	   BD	  Pharmingen™	  
CD34	   APC-­‐Cy7	   581	   Biolegend	  
CD38	   APC	   HB7	   BD	  Pharmingen™	  
CD90	   PE	   5E10	   e	  Bioscience	  
CD3	   APC	   UCHT1	   BD	  Pharmingen™	  
Annexin-­‐V	   FITC	   VAA-­‐33	   BD	  Pharmingen™	  
	  
For	  each	  sample,	  a	  cell	  suspension	  containing	  20	  x	  106	  NC/mL	  in	  Dulbecco’s	  phosphate	  
buffered	  saline	  (D-­‐PBS)	  and	  2	  %	  fetal	  bovine	  serum	  (FBS)	  (both	  Sigma	  Life	  Science,	  St.	  Louis,	  
MO)	  was	  prepared.	  	  Eight	  testing	  tubes	  with	  different	  cell	  concentrations	  were	  prepared.	  Six	  
tubes	  were	  used	  for	  HSC/P	  subset	  identification,	  one	  for	  CD3	  evaluation,	  and	  one	  for	  the	  
ALDEFLUOR	  assay.	  One	  hundred	  microliters	  of	  the	  prepared	  suspension	  were	  transferred	  to	  
the	  first	  set	  of	  tubes	  (1-­‐3)	  to	  obtain	  2	  X	  106	  cells	  for	  staining.	  Two	  hundred	  microliters	  were	  
transferred	  to	  the	  second	  set	  of	  tubes	  (4-­‐6)	  to	  obtain	  4	  X	  106	  cells.	  Fifty	  microliters	  were	  
transferred	  to	  the	  CD3	  evaluation	  tube	  to	  obtain	  1	  X	  106	  cells	  concentration,	  and	  150	  µL	  
were	  transferred	  to	  the	  ALDEFLUOR	  testing	  tube	  to	  obtain	  3	  X	  106	  cells	  for	  staining.	  
Staining	  procedure	  
Cells	  were	  suspended	  in	  3	  mL	  of	  D-­‐PBS	  supplemented	  with	  2	  %	  FBS	  and	  centrifuged	  at	  220	  x	  
g	  for	  7	  min.	  The	  supernatants	  were	  then	  discarded	  and	  the	  cell	  pellets	  were	  re-­‐suspended	  
directly	  with	  the	  isotype	  control	  or	  murine	  anti-­‐human	  monoclonal	  antibodies	  (20µL	  per	  106	  
cells)	  and	  incubated	  for	  20	  min.	  in	  a	  4-­‐6°C	  refrigerator.	  The	  list	  of	  antibodies	  added	  to	  each	  
tube	  is	  shown	  in	  Table	  2.	  Cells	  were	  then	  incubated	  for	  15	  min.	  at	  RT	  with	  lysing	  buffer	  (BD	  
Bioscience,	  San	  Jose,	  CA)	  to	  lyse	  the	  residual	  RBC.	  Tubes	  were	  then	  centrifuged	  at	  220	  x	  g	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for	  7	  min.	  and	  the	  cell	  pellets	  washed	  once	  with	  1	  mL	  of	  D-­‐PBS/2	  %	  FBS	  solution.	  After	  
washing,	  the	  cell	  pellets	  were	  re-­‐suspended	  in	  100	  µL	  1:10	  annexin-­‐V	  binding	  buffer	  (BD	  
bioscience,	  San	  Jose,	  CA).	  To	  standardize	  the	  volume	  of	  viability	  staining	  added	  to	  each	  
tube,	  7-­‐AAD	  and	  annexin-­‐V	  solution	  was	  prepared	  in	  a	  staining	  buffer	  (SB)	  (BD	  
Pharmingen™,	  San	  Jose,	  CA)	  and	  proper	  amount	  of	  the	  solution	  was	  added	  to	  each	  tube.	  
The	  cell	  suspensions	  were	  then	  incubated	  for	  15	  min.	  at	  RT	  and	  then	  placed	  on	  ice	  and	  
analyzed	  immediately.	  Data	  acquisition	  was	  performed	  using	  a	  dual	  laser	  FACSCanto	  II	  (BD	  
bioscience)	  flow	  cytometer	  and	  data	  analyzed	  using	  FACSDiva	  software	  (BD	  bioscience,	  San	  
Jose,	  CA).	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1	   X	   	   	   	   	   X	   X	   	   X	   	  
2	   X	   	   X	   	   	   	   X	   	   X	   	  
3	   X	   	   X	   X	   	   	   	   	   X	   	  
4	   	   	   X	   X	   	   	   	   X	   X	   	  
5	   	   	   X	   X	   X	   	   	   	   X	   	  
6	   	   	   X	   X	   X	   	   	   	   X	   	  
CD3	   	   X	   	   	   	   	   	   	   X	   	  
ALDEFLUOR	   X	   	   X	   X	   	   	   	   	   	   X	  
Aldehyde	  dehydrogenase	  enzyme	  
A	  high	  level	  of	  aldehyde	  dehydrogenase	  (ALDH)	  activity	  has	  been	  proposed	  to	  be	  a	  common	  
feature	  of	  stem	  cells.	  11	  	  The	  ALDEFLUOR™	  reagent	  kit	  (STEMCELL	  Technologies)	  was	  used	  in	  
combination	  with	  anti-­‐CD45-­‐PE,	  anti-­‐CD34-­‐APC-­‐Cy7	  and	  anti-­‐CD38-­‐APC	  to	  detect	  cells	  with	  
high	  ALDH	  levels.	  The	  activated	  ALDEFLUORTM	  Reagent,	  BODIPY™-­‐	  aminoacetaldehyde	  
(BAAA)	  is	  a	  fluorescent	  non-­‐toxic	  substrate	  for	  ALDH,	  which	  freely	  diffuses	  into	  intact	  and	  
viable	  cells.	  In	  the	  presence	  of	  ALDH,	  BAAA	  is	  converted	  into	  BODIPY™-­‐aminoacetate	  (BAA),	  
which	  is	  retained	  inside	  the	  cells.	  The	  amount	  of	  fluorescent	  reaction	  product	  is	  
proportional	  to	  the	  ALDH	  activity	  in	  the	  cells	  and	  is	  measured	  using	  a	  flow	  cytometer.	  	  
To	  stain	  the	  cells	  with	  ALDEFLUOR,	  3	  X	  106	  cells	  were	  washed	  with	  3	  mL	  of	  D-­‐PBS/2	  %	  FBS.	  
RBCs	  were	  lysed	  using	  2	  mL	  lysing	  buffer	  and	  washed	  with	  1	  mL	  of	  the	  D-­‐PBS	  /2	  %	  FBS.	  Cells	  
were	  then	  diluted	  with	  1	  mL	  of	  pre-­‐warmed	  –	  at	  RT—	  ALDEFLUOR™	  buffer	  and	  5	  µL	  of	  
activated	  ALDEFLUOR™	  reagent.	  Five	  hundred	  microliters	  of	  the	  suspension	  were	  
immediately	  transferred	  to	  1.5	  mL	  microtiter	  tube	  that	  contained	  5	  µL	  of	  ALDEFLUOR™	  
control	  reagent.	  The	  rest	  of	  the	  suspension	  was	  transferred	  to	  another	  1.5	  mL	  microtiter	  
tube	  and	  both	  incubated	  for	  30	  min.	  at	  37°C.	  After	  incubation,	  tubes	  were	  centrifuged	  for	  7	  
min.	  at	  220g	  then	  cells	  were	  stained	  with	  CD45-­‐PE,	  CD34-­‐APC-­‐Cy7	  and	  CD38-­‐APC	  (Table	  2).	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After	  staining	  cells	  were	  washed	  in	  1	  mL	  of	  the	  ALDEFLUOR™	  buffer	  then	  re-­‐suspended	  with	  
100µL	  of	  the	  ALDEFLUOR™	  buffer	  and	  stained	  with	  10µL	  7-­‐AAD	  for	  15	  min.	  After	  incubation	  
400	  µL	  of	  the	  ALDEFLUOR™	  buffer	  was	  added	  and	  the	  tubes	  kept	  on	  ice	  until	  acquisition.	  
Gating	  strategies	  
Cell	  subset	  identification	  
Flow	  cytometry	  was	  used	  to	  identify	  hematopoietic	  cell	  subsets	  that	  vary	  in	  maturity.	  	  	  The	  
CD34+,	  CD38-­‐and	  CD90+	  cell	  is	  the	  most	  immature	  cell	  while	  the	  CD3+	  T-­‐cell	  is	  the	  most	  
mature	  cell	  of	  interest.	  The	  first	  set	  of	  tubes	  (1-­‐3)	  was	  used	  to	  identify	  the	  WBC	  (CD45+),	  
and	  the	  CD34+	  (CD45+	  and	  CD34+),	  CD38-­‐	  (CD45+,	  CD34+	  and	  CD38-­‐)	  and	  CD38+	  (CD45+,	  
CD34+	  and	  CD38+)	  progenitor	  cells.	  The	  second	  set	  of	  tubes	  (4-­‐6)	  was	  used	  to	  identify	  the	  
more	  primitive	  CD90-­‐	  (CD34+,	  CD38-­‐	  and	  CD90-­‐)	  MPP	  and	  the	  CD90+	  (CD34+,	  CD38-­‐	  and	  
CD90+)	  stem	  cells.	  The	  T-­‐cells	  (CD3+)	  were	  identified	  from	  the	  CD3	  tube.	  The	  cell	  subset	  
phenotypes	  are	  summarized	  in	  Table	  3.	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Table	  3:	  Cell	  subset	  phenotypes.	  
Cell	  subset	   CD	  Markers	  
CD90+	   CD34+,	  CD38-­‐,	  CD90+	  
CD90-­‐	   CD34+,	  CD38-­‐,	  CD90-­‐	  
ALDbr	   CD45+,	  CD34+,	  CD38-­‐,	  ALDbr,	  7-­‐AAD-­‐	  
CD38-­‐	   CD45+,	  CD34+,	  CD38-­‐	  
CD38+	   CD45+,	  CD34+,	  CD38+	  
CD34+	   CD45+,	  CD34+	  
WBC	   CD45+	  
T	  cell	   CD3+	  
	  
Different	  gating	  strategies	  were	  followed	  for	  the	  different	  tube	  sets.	  The	  International	  
Society	  of	  Hematotherapy	  and	  Graft	  Engineering	  (ISHAGE)	  guidelines	  for	  CD34+	  
determination	  were	  followed	  for	  the	  first	  set	  of	  tubes	  (1-­‐3)	  (Figure	  4-­‐A).	  32	  For	  the	  next	  set	  of	  
tubes	  (4-­‐6),	  	  the	  CD34	  gate	  was	  used	  directly	  after	  the	  light	  scatter	  gate,	  followed	  by	  CD38	  
and	  CD90	  gates	  (Figure	  4-­‐B).	  	  The	  same	  strategy	  used	  for	  the	  first	  set	  of	  tubes	  (1-­‐3)	  was	  
followed	  for	  The	  ALDEFLUOR™	  assay	  analysis.	  The	  ALDbr	  region	  was	  determined	  from	  the	  
control	  tube.	  The	  ALDbr,	  7-­‐AAD-­‐	  cells	  were	  identified	  from	  the	  CD45+,	  CD34+	  and	  CD38-­‐	  
population	  (Figure	  5).	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Figure	  4:	  Gating	  strategies	  
(A)	  Guidelines	  followed	  for	  the	  first	  set	  of	  tubes	  (1-­‐3)	  P1	  used	  to	  exclude	  RBCs	  and	  debris	  followed	  
by	  CD45	  then	  CD34.	  P2	  used	  to	  exclude	  the	  CD34+,	  CD45	  bright	  cells	  and	  P3	  in	  light	  scatter	  plot	  used	  
to	  exclude	  debris.	  The	  CD38	  fluorscence	  was	  gated	  on	  the	  CD45+	  CD34+	  (P3)	  population.	  .(B)	  Gating	  
strategies	  for	  the	  second	  set	  of	  tubes	  (4-­‐6).	  P1	  used	  to	  exclude	  RBCs	  and	  debris	  followed	  by	  CD34	  
then	  P2	  to	  exclude	  debris.	  Then	  CD38	  gates	  were	  determined	  from	  P2	  population,	  and	  the	  CD90	  
fluorescence	  was	  gated	  on	  the	  CD38-­‐	  population.	  FSC-­‐A	  =	  forward	  scatter	  (area).	  SSC-­‐A	  =	  side	  scatter	  
(area).	  
B	  










	   	   	  
Figure	  5:	  ALDEFLUOR	  assay	  evaluation	  
Measurement	  of	  ALDH	  content	  of	  CD34+	  CD38-­‐	  cells.	  	  (A)	  ALDEFLUOR-­‐FITC	  vs	  side	  scatter	  plot	  used	  
to	  determine	  the	  ALDbr	  region	  from	  the	  control	  tube.	  (B)	  The	  ALDbr	  cells	  are	  determined	  from	  the	  
testing	  tube.	  
	  
The	  CD3+	  population	  was	  evaluated	  from	  tube	  stained	  with	  anti-­‐CD3-­‐APC,	  7-­‐AAD	  and	  
annexin-­‐V-­‐FITC	  (Figure	  6).	  
	  
Figure	  6:	  Gating	  strategy	  for	  the	  CD3+	  population.	  
P1	  was	  used	  to	  exclude	  part	  of	  the	  RBC.	  CD3+	  population	  was	  selected	  and	  gated	  back	  to	  a	  light	  
scatter	  plot	  to	  narrow	  it	  to	  the	  lymphocyte	  region.	  FSC-­‐A	  =	  forward	  scatter	  (area).	  SC	  =	  side	  scatter.	  
	  
	  
	   25	  
Viability	  evaluation	  
In	  this	  study,	  viable	  cells	  were	  defined	  as	  7-­‐AAD	  negative	  and	  annexin-­‐V	  negative.	  7-­‐AAD	  is	  
measuring	  the	  cells’	  viability	  by	  testing	  their	  ability	  to	  uptake	  the	  viable	  stain	  7-­‐AAD.	  Since	  
viable	  cells	  have	  an	  intact	  membrane,	  they	  will	  not	  be	  stained	  with	  7-­‐AAD.	  Annexin-­‐V	  is	  
measuring	  an	  Apoptosis	  (Apo)	  marker,	  which	  is	  loss	  of	  membrane	  phospholipid	  symmetry.	  
Phosphatidylserine	  (PS)	  is	  normally	  expressed	  in	  the	  cytoplasmic	  layer	  of	  the	  plasma	  
membrane.	  Upon	  apoptosis,	  PS	  is	  trans-­‐located	  to	  the	  outer	  layer.	  PS	  expression	  plays	  an	  
important	  role	  in	  the	  recognition	  and	  removal	  of	  apoptotic	  cells	  by	  macrophages.	  33	  	  Annexin	  
V	  dependent	  phospholipid-­‐binding	  protein	  has	  a	  high	  affinity	  for	  PS,	  which	  makes	  it	  possible	  
to	  measure	  apoptosis.	  Using	  annexin-­‐V	  in	  combination	  with	  7-­‐AAD	  allows	  us	  to	  identify	  the	  
apoptotic	  cells,	  which	  are	  the	  7-­‐AAD	  negative	  and	  annexin-­‐V	  positive	  population	  (Figure	  7).	  
34	  The	  percentage	  of	  different	  cell	  subsets	  at	  apoptotic	  and	  necrotic	  stages	  was	  compared	  
among	  different	  storage	  conditions.	  
	  
Figure	  7:	  Evaluation	  of	  viability.	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Recovery	  calculations	  
Post	  storage	  total	  nucleated	  cell	  (TNC)	  recovery	  was	  calculated	  using	  the	  following	  formula:	  	  
	  
Recovery	  of	  various	  cell	  subsets	  was	  calculated	  using	  the	  following	  equation:	  	  	  
	  	  
	  
Analysis	  of	  viable	  cell	  recovery	  of	  the	  various	  cell	  subsets	  was	  performed	  to	  determine	  
whether	  the	  cryopreservation	  or	  storage	  conditions	  tested	  have	  more	  of	  an	  effect	  on	  one	  
population	  or	  another,	  since	  total	  cell	  viability	  might	  be	  high,	  but	  progenitor	  cell	  viability	  
might	  not.	  	  
In-­‐vitro	  functional	  assessment	  
Colony	  forming	  unit	  assay	  
A	  CFU	  assay	  was	  performed	  for	  post-­‐processing	  samples,	  all	  post-­‐thaw	  samples	  and	  for	  48	  h	  
and	  72	  h	  hypothermic	  stored	  samples.	  The	  CFU	  assay	  was	  performed	  using	  methylcellulose	  
colony	  assay	  medium	  (Methocult®	  H4434,	  Stem	  Cell	  Technologies,	  Vancouver,	  Canada),	  
which	  is	  supplemented	  with	  SCF,	  EPO,	  IL-­‐3	  (interleukin	  3)	  and	  GM-­‐CSF	  (Granulocyte-­‐
macrophage	  colony	  stimulating	  factor).	  Two	  cell	  concentrations	  (1X104	  cells/mL	  and	  3X104	  
cells/mL,	  in	  IMDM)	  were	  tested	  to	  ensure	  a	  sufficient	  number	  of	  colonies	  to	  count.	  The	  cells	  
were	  inoculated	  into	  3	  mL	  Methocult®	  H4434	  medium.	  	  Blunt	  end	  needles	  (Stem	  Cell	  
Technologies)	  attached	  to	  3	  mL	  syringes	  were	  used	  to	  transfer	  1.1	  mL	  to	  35	  mm	  culture	  
dishes	  35	  (Stem	  Cell	  Technologies).	  Culture	  dishes	  were	  left	  in	  a	  humidified	  37°C	  incubator	  
	  
Post	  storage	  TNC	  count	  	  
Fresh	  sample	  TNC	  count	  	  
	  
	  	  
%	  TNC	  recovery	  =	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  X100	  
%	  Recovery	  of	  viable	  cells	  subset	  %=	  
Post	  storage	  cell	  subset	  %	  X	  Subset	  viability	  %	  X	  Post	  storage	  TNC	  count	  	  	  	  	  	  X	  100	  
Fresh	  sample	  cell	  subset	  %	  X	  Subset	  viability	  %	  X	  Fresh	  sample	  TNC	  count	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with	  5	  %	  CO2	  (OLYMPYS	  IMT-­‐2)	  for	  14	  days.	  Burst-­‐forming	  unit	  (BFU),	  colony-­‐forming-­‐unit	  
granulocyte	  monocyte	  (CFU-­‐GM),	  and	  colony-­‐forming-­‐unit	  granulocyte	  erythroid	  monocyte	  
megakaryocyte	  (CFU-­‐GEMM)	  colonies	  greater	  than	  50	  cells	  were	  counted	  using	  an	  inverted	  
microscope.	  The	  average	  colony	  count	  from	  2	  plates	  was	  calculated	  and	  used	  for	  analysis.	  
Proliferation	  assay	  
Twenty	  two	  million	  nucleated	  cells	  were	  cultured	  in	  six	  well	  plates	  containing	  2	  mL/well	  of	  
StemSpan®	  SFEM	  serum	  free	  medium	  (STEMCELL	  Technologies)	  with	  30	  μg/mL	  Human	  LDL	  
(low	  density-­‐lipoprotein)	  (STEMCELL	  Technologies)	  and	  a	  cytokine	  cocktail	  (StemSpan®	  
CC110)	  that	  included	  stem	  cell	  factor	  (SCF),	  Flt3-­‐ligand	  and	  thrombopoietin	  (TPO)	  36	  ,	  at	  a	  
1:100	  dilution—according	  to	  the	  manufacturer’s	  instructions.	  	  Plates	  were	  incubated	  at	  37°C	  
in	  5	  %	  CO2	  and	  cells	  were	  analyzed	  after	  48	  h	  Bromodeoxyuridine	  (BrdU)	  uptake	  assay	  (BD	  
Bioscience)	  accompanied	  with	  CD45,	  CD34	  and	  CD38	  staining	  was	  used	  to	  evaluate	  the	  
proliferation	  potential	  of	  the	  CD38+	  (CD45+,	  CD34+	  and	  CD38+)	  population.	  
BrdU	  incorporation	  assay	  
Bromodeoxyuridine	  (BrdU)	  is	  an	  analog	  of	  the	  DNA	  precursor	  thymidine	  that	  is	  incorporated	  
into	  newly	  synthesized	  DNA	  as	  cells	  progress	  through	  the	  S	  phase	  of	  the	  cell	  cycle.	  The	  
incorporated	  BrdU	  is	  stained	  with	  specific	  FITC	  conjugated	  anti-­‐BrdU	  antibodies.	  The	  
immunofluorescent	  staining	  of	  incorporated	  BrdU	  and	  flow	  cytometric	  analysis	  provided	  a	  
high-­‐resolution	  technique	  to	  determine	  the	  frequency	  cells	  that	  have	  synthesized	  DNA	  
during	  the	  S	  phase	  of	  the	  cell	  cycle	  (Figure	  8).	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Figure	  8:	  Flow	  cytometry	  analysis	  of	  BrdU	  incorporation	  assay.	  
BrdU-­‐FITC	  and	  7-­‐AAD	  plot	  was	  used	  to	  determine	  the	  cell	  cycle	  stages.	  G0/G1	  is	  the	  cell’s	  quiescence	  
stage	  (non-­‐proliferating	  cells).	  S	  phase	  is	  the	  DNA	  synthesis	  phase	  and	  G2/M	  is	  after	  DNA	  
proliferation	  when	  the	  cell’s	  DNA	  duplicated.	  
To	  perform	  the	  BrdU	  uptake	  assay	  in	  proliferating	  cells,	  the	  cultured	  cell	  suspension	  was	  
transferred	  to	  5	  mL	  sterile	  tubes	  (Becton	  Dickinson,	  Franklin	  Lakes,	  NJ)	  centrifuged	  for	  5	  
min.	  at	  170	  x	  g	  then	  washed	  once	  with	  2	  mL	  of	  D-­‐PBS/	  2	  %	  FBS	  (BD,	  San	  Diego,	  CA).	  Cells	  
were	  re-­‐suspended	  in	  1	  mL	  of	  StemSpan	  SFEM	  supplemented	  with	  10	  µL	  of	  23X	  BrdU	  (1mM	  
in	  1X	  D-­‐PBS)	  and	  incubated	  for	  45	  min.	  at	  37°C	  and	  5%	  CO2.	  Cells	  were	  centrifuged	  at	  200	  x	  g	  
for	  5	  min.	  then	  washed	  with	  1	  mL	  of	  SB	  then	  stained	  with	  anti-­‐CD45-­‐PE,	  anti-­‐CD34-­‐APC-­‐Cy7	  
and	  anti-­‐CD38-­‐APC.	  Cells	  were	  then	  suspended	  with	  100	  µL	  of	  BD	  Cytofix/Cytoperm™	  buffer	  
and	  incubated	  for	  20	  min.	  at	  RT	  for	  fixation	  and	  permeabilization	  then	  washed	  with	  1	  mL	  of	  
1X	  BD	  perm/	  wash™	  buffer.	  Cells	  were	  incubated	  with	  100	  µL	  of	  BD	  Cytoperm™	  buffer	  for	  10	  
min.	  on	  ice,	  washed	  with	  1	  mL	  of	  1X	  BD	  perm/	  wash™	  buffer	  and	  treated	  with	  100	  µL	  of	  
diluted	  DNase	  (30	  μg)	  to	  expose	  the	  incorporated	  BrdU,	  then	  stained	  with	  1:50	  diluted	  anti-­‐
BrdU	  FITC	  conjugated	  antibodies.	  To	  stain	  the	  total	  DNA	  level,	  treated	  cells	  were	  stained	  
with	  20	  µL	  7-­‐AAD.	  Samples	  were	  analyzed	  by	  flow	  cytometry	  to	  detect	  the	  levels	  of	  
synthesized	  DNA	  in	  the	  CD45+,	  CD34+,CD38+	  population.	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STATISTICAL	  ANALYSIS	  
Data	  were	  recorded	  as	  mean	  ±	  standard	  deviation	  (SD).	  Statistical	  significance	  was	  
evaluated	  using	  the	  paired	  or	  non-­‐paired	  Student’s	  t-­‐test	  and	  correlation	  coefficient	  (R).	  The	  
significance	  threshold	  was	  set	  at	  p-­‐value	  <	  0.05.	  Data	  were	  analyzed	  using	  Excel	  
2011(Microsoft®	  Excel®	  for	  Mac	  2011,	  v14.32	  (130206).	  Microsoft	  Co.	  Seattle,	  WA).
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RESULTS	  
RBC	  depletion	  
Commercially	  available	  PrepaCyte®	  solution	  was	  used	  to	  perform	  RBC	  depletion.	  TNC	  count	  
was	  performed	  before	  and	  after	  the	  process.	  In	  fresh	  CBU,	  the	  volume	  of	  the	  unit	  varied	  
between	  89	  and	  117	  mL	  ,	  and	  the	  cell	  count	  varied	  between	  340X106	  –	  820X106	  TNC.	  	  
PrepaCyte®	  depleted	  an	  average	  of	  98%	  of	  the	  RBC,	  with	  an	  average	  viable	  TNC	  recovery	  of	  
75	  ±	  19%	  (Table	  4).	  
Table	  4:	  TNC	  and	  RBC	  recovery	  after	  RBC	  depletion.	  	  
	   	   Pre-­‐RBC	  Depletion	   Post-­‐RBC	  Depletion	  
Volume	  (mL)	   	   102	  ±	  10	   	  




18	  ±	  6	  
	  
0.4	  ±	  0.1	  
2	  ±	  1	  
Viable	  TNC	  
Viable	  TNC	  recovery	  
No.	  
	  %	  
450X106	  ±	  160X106	  
	  
320X106	  ±	  99X106	  
75	  ±	  19	  
CBU	  processed	  with	  PrepaCyte®	  for	  RBC	  depletion.	  Data	  expressed	  as	  mean	  ±	  SD.	  (N=7).	  	  
After	  RBC	  depletion,	  fresh	  samples	  were	  analyzed	  for	  the	  viability	  of	  each	  cell	  subset.	  There	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Cell	  subset	  concentrations	  from	  fresh	  CBU	  after	  RBC	  depletion.	  Data	  expressed	  as	  the	  mean	  
percentage	  ±	  SD	  (N=6).	  	  
Cryopreservation	  	  
Evaluation	  of	  viable	  cell	  subset	  recovery	  
Cryopreserved	  samples	  were	  thawed	  and	  diluted	  1:12	  with	  pre-­‐cooled	  TM.	  Samples	  were	  
taken	  immediately	  after	  dilution	  and	  were	  analyzed	  for	  cell	  count	  and	  flow	  cytometry.	  	  
Total	  nucleated	  cell	  (TNC)	  recovery	  was	  similar	  in	  all	  post-­‐thaw	  samples.	  	  TNC	  recovery	  
averaged	  90%	  after	  cryopreservation	  in	  the	  conventional	  cryopreservation	  media,	  87%	  
when	  using	  the	  CryoStor	  5	  and	  91%	  when	  using	  the	  CryoStor	  10,	  but	  these	  differences	  were	  
not	  statistically	  significant	  (Table	  6).	  	  Recovery	  of	  viable	  cells	  was	  unexpectedly	  low	  with	  all	  
cryopreservation	  media.	  	  Although	  there	  was	  a	  trend	  toward	  improved	  post	  thaw	  viable	  cell	  
recovery	  after	  cryopreservation	  in	  the	  conventional	  medium,	  the	  differences	  in	  the	  recovery	  
of	  viable	  cells	  between	  cryostorage	  media	  were	  not	  statistically	  significant	  (p-­‐value	  0.2-­‐0.8)	  
(Table	  6,	  Figure	  9).	  
	   	  
Cell	  subset	   Cell	  Surface	  Antigen	   %	  Concentration	  
CD90+	   CD34+,	  CD38-­‐	  and	  CD90+	   0.013	  ±	  0.008	  
CD90-­‐	   CD34+,	  CD38-­‐	  and	  CD90-­‐	   0.096	  ±	  0.048	  
ALDbr	   CD45+,	  CD34+,	  CD38-­‐,	  ALDbr,	  7-­‐AAD-­‐	   0.073	  ±	  0.064	  
CD38-­‐	   CD45+,	  CD34+,	  CD38-­‐	   0.090	  ±	  0.096	  
CD38+	   CD45,	  CD34+,	  CD38+	   0.175	  ±	  0.084	  
CD34+	   CD45+,	  CD34+	   0.234	  ±	  0.171	  
WBC	   CD45+	   88	  ±	  7	  
T	  cell	   CD3+	   18	  ±	  10	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Table	  6:	  Post-­‐thaw	  recovery	  of	  TNC	  and	  viable	  TNC	  
	   	   Pre-­‐storage	   Post-­‐thaw	  






250X106	  ±	  38X106	   55X106	  ±	  27X106	  
90	  ±	  7	  
53X106	  ±	  24X106	  
87	  ±	  6	  
0.8	  
56X106	  ±	  20X106	  







197X106	  ±	  26X106	   23X106±	  15	  X106	  
51±5	  




48	  ±	  10	  
0.2	  
TNC	  and	  viable	  TNC	  count	  in	  fresh	  and	  post-­‐thaw	  samples.	  P-­‐value	  compared	  the	  conventional	  with	  
CryoStor	  media.	  Data	  are	  presented	  as	  the	  mean	  ±	  SD	  (N=3).	  
	  	  
	  
Figure	  9:	  Post-­‐thaw	  viable	  TNC	  recovery.	  	  
Viable	  TNC	  recovery	  was	  calculated	  using	  the	  percentage	  of	  viable	  CD45+.	  Recovery	  results	  are	  
expressed	  as	  mean	  ±	  SD.	  
	  
The	  post-­‐thaw	  viability	  (%7-­‐AAD	  neg./annexin-­‐V	  neg.)	  of	  the	  entire	  CD45+	  WBC	  population	  
was	  surprisingly	  low,	  ranging	  from	  25	  –	  50%	  for	  the	  3	  samples,	  although	  the	  difference	  in	  
post-­‐thaw	  viability	  between	  the	  3	  samples	  was	  not	  statistically	  significant.	  	  The	  more	  
primitive	  hematopoietic	  progenitor	  cell	  subsets	  (CD90+,	  CD90-­‐,	  CD38-­‐,	  CD38+	  and	  CD34+)	  
had	  a	  higher	  post	  thaw	  viability	  than	  the	  CD45+	  cells	  and,	  although	  not	  statistically	  
significant,	  there	  seemed	  to	  be	  a	  trend	  toward	  improved	  post-­‐thaw	  viability	  of	  these	  
subsets	  when	  using	  CryoStor	  5.	  	  Similarly,	  the	  post	  thaw	  viability	  of	  the	  mature	  CD3+	  T	  cell	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for	  the	  progenitor	  cell	  populations,	  but	  with	  this	  subset,	  although	  not	  statistically	  significant,	  
it	  appeared	  that	  the	  post	  thaw	  viability	  was	  slightly	  better	  when	  using	  CS	  10.	  	  The	  lowest	  
post-­‐thaw	  viability	  occurred	  in	  the	  CD90-­‐	  population,	  although	  the	  number	  of	  cells	  analyzed	  
was	  quite	  small	  and	  the	  variability	  in	  the	  measurement	  quite	  large,	  so	  the	  difference	  was	  
not	  statistically	  significant.	  	  A	  graphical	  representation	  of	  the	  post-­‐thaw	  viability	  results	  is	  
shown	  in	  Figure	  10.	  
	  
Figure	  10:	  Viability	  evaluation	  of	  post-­‐thaw	  samples.	  
Viability	  evaluation	  using	  7-­‐AAD	  neg./annexin-­‐V	  neg.	  Data	  are	  presented	  as	  percentage	  mean	  ±	  SD.	  
	  
Since	  there	  may	  be	  deleterious	  effects	  of	  cryopreservation	  on	  cells	  that	  go	  undetected	  by	  
analyzing	  post-­‐thaw	  viability	  alone,	  we	  evaluated	  the	  percentage	  of	  the	  cells	  undergoing	  
apoptosis	  (%7-­‐AAD	  neg.,	  annexin-­‐V	  pos.)	  after	  cryopreservation	  and	  thawing.	  	  In	  general,	  
there	  was	  less	  apoptosis	  after	  freezing	  and	  thawing	  the	  hematopoietic	  progenitor	  cell	  
subsets	  (CD90+,	  CD38-­‐,	  CD38+	  and	  CD34+)	  ,	  than	  there	  was	  for	  the	  CD3+	  T	  cell	  population	  or	  
for	  the	  entire	  CD45+	  WBC	  population	  (Figure	  11).	  	  As	  with	  post-­‐thaw	  viability,	  the	  highest	  
amount	  of	  apoptosis	  amongst	  the	  progenitor	  cell	  populations	  occurred	  with	  the	  CD90-­‐	  
population,	  although	  again	  the	  number	  of	  cells	  analyzed	  was	  quite	  small	  and	  the	  variability	  
in	  the	  measurement	  quite	  large,	  so	  the	  difference	  was	  not	  statistically	  significant.	  	  There	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freezing	  with	  the	  three	  different	  cryopreservation	  media	  (p-­‐value	  0.3-­‐1).	  	  A	  graphical	  
representation	  of	  the	  percentage	  of	  cells	  undergoing	  apoptosis	  after	  freezing	  and	  thawing	  is	  
shown	  in	  Figure	  11.	  	  	  
	  
Figure	  11:	  Evaluation	  of	  post-­‐thaw	  apoptosis.	  
Flow	  cytometric	  apoptosis	  evaluation	  of	  post-­‐thaw	  samples.	  Data	  are	  expressed	  as	  the	  mean	  ±	  SD.	  
	  
Recovery	  of	  viable	  cells	  post	  thaw	  varied	  amongst	  the	  various	  subsets	  analyzed.	  	  Despite	  a	  
large	  variability	  in	  the	  results	  and	  despite	  a	  lack	  of	  statistical	  significance	  (P-­‐value	  0.2-­‐1.0),	  It	  
appeared	  that	  perhaps	  the	  CD90+	  and	  CD90-­‐	  subsets	  survived	  the	  freeze/thaw	  process	  
better	  when	  they	  were	  stored	  in	  the	  conventional	  cryopreservation	  medium	  than	  either	  of	  
the	  CryoStor	  medias,	  whereas	  it	  appeared	  that	  the	  CryoStor	  10	  media	  worked	  better	  for	  the	  
CD3+	  T	  cells,	  and	  it	  appeared	  the	  other	  subsets	  all	  survived	  equally	  in	  the	  three	  
cryopreservation	  medias	  (Figure	  12).	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Figure	  12:	  Post-­‐thaw	  cell	  recovery.	  
Data	  are	  presented	  as	  the	  mean	  ±	  SD.	  
	  Recovery	  of	  ALDEFLUOR	  Bright	  cells	  
Perhaps	  because	  there	  were	  so	  few	  CD45+,	  CD34+,	  CD38-­‐	  ALDbr	  cells	  in	  the	  3	  cord	  blood	  
samples	  tested,	  there	  was	  a	  large	  variation	  in	  the	  post-­‐thaw	  recovery	  calculations,	  and	  
therefore	  no	  statistically	  significant	  differences	  between	  the	  3	  cryopreservation	  medias	  
tested	  (Table	  7;	  Figure	  13).	  	  The	  post-­‐thaw	  viability	  of	  the	  ALDbr	  cells	  was	  >90%	  for	  all	  three	  
cryopreservation	  medias	  also.	  	  	  
Table	  7:	  Post-­‐thaw	  ALDEFLUOR	  evaluation	  
	   Fresh	   Conventional	   CryoStor	  5®	   CryoStor	  10®	  
ALDbr	  %	  
P-­‐value	  
0.061	  ±	  0.028	   0.036	  ±	  0.021	   0.029	  ±	  0.011	  
0.7	  




	   74	  ±	  74	   59	  ±	  53	  
0.8	  
65	  ±	  56	  
0.9	  
P-­‐values	  compared	  the	  variation	  in	  recovery	  and	  ALDbr	  cells	  in	  conventional	  and	  CryoStor	  media.	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Figure	  13:	  Post-­‐thaw	  recovery	  of	  ALDEFLUOR	  bright	  cells.	  
Recovery	  of	  ALDbr	  cells	  from	  each	  sample.	  	  
	  
Clonogenic	  capacity	  
To	  determine	  the	  clonogenic	  capacity	  of	  post-­‐thawed	  samples,	  cells	  were	  inoculated	  in	  
methylcellulose	  media	  and	  evaluated	  for	  the	  number	  of	  BFU-­‐E,	  CFU-­‐GM	  and	  CFU-­‐GEMM	  
colonies	  that	  grew	  for	  every	  105	  cells	  plated.	  	  Results	  are	  shown	  in	  Table	  8	  and	  in	  Figure	  14.	  	  
Whether	  analyzing	  total	  colony	  count	  or	  each	  individual	  colony	  type,	  more	  colonies	  grew	  
after	  cryopreservation	  in	  CryoStor	  10	  than	  in	  either	  of	  the	  other	  two	  cryopreservation	  
medias,	  although	  the	  differences	  were	  not	  statistically	  significant.	  	  
Table	  8:	  Clonogenic	  capacity	  of	  post-­‐thaw	  samples	  
	   Conventional	   CryoStor5	   CryoStor10	  
BFU-­‐E	  
P-­‐value	  
68	  ±	  41	   72	  ±	  33	  
0.9	  




53	  ±	  5	   49	  ±	  14	  
0.7	  




3	  ±	  1	   2	  ±	  2	  
0.5	  




124	  ±	  44	   124	  ±	  44	  
1.0	  
144	  ±	  46	  
0.6	  
Data	  presented	  as	  the	  mean	  number	  of	  colonies	  counted	  /105	  cells	  plated	  ±	  SD.	  P-­‐values	  compared	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Figure	  14:Clonogenic	  capacity	  of	  post-­‐thawed	  samples	  from	  each	  unit.	  
Proliferation	  capacity	  
	  Proliferation	  capacity	  was	  determined	  by	  inoculating	  thawed	  cells	  in	  StemSpan®	  SFEM	  
serum	  free	  medium	  supplemented	  with	  a	  cytokine	  cocktail	  designed	  to	  support	  
hematopoietic	  progenitor	  cell	  proliferation.	  	  After	  48	  h	  incubation,	  cells	  were	  washed	  and	  
analyzed	  for	  proliferation	  capacity	  using	  a	  BrdU	  incorporation	  assay.	  Cell	  cycle	  stages	  were	  
determined	  using	  the	  BrdU-­‐FITC	  and	  7-­‐AAD	  plots.	  Evaluation	  was	  based	  on	  the	  percentage	  
of	  CD38+	  (CD45+,	  CD34+	  and	  CD38+)	  that	  proliferated	  (were	  in	  either	  S	  phase,G2,	  or	  M)	  or	  
remained	  quiescent	  (in	  phase	  G0	  or	  G1).	  	  The	  CD38+	  progenitor	  cells	  cryopreserved	  with	  
CS10	  seemed	  better	  able	  to	  proliferate	  after	  thawing	  than	  if	  frozen	  in	  either	  CS5	  or	  the	  
conventional	  media,	  since	  there	  were	  more	  cells	  in	  either	  S	  or	  G2/M	  phases	  of	  the	  cell	  cycle	  
after	  48	  hrs	  in	  culture,	  however	  this	  difference	  was	  not	  statistically	  significant	  (p-­‐value	  0.07	  
–	  0.8).	  Results	  are	  shown	  in	  Table	  9	  and	  Figure	  15.	  	  
Table	  9:	  Proliferation	  potential	  of	  post-­‐thaw	  samples	  





25	  ±	  16	  
0.8	  




67	  ±	  12	  
	  
66	  ±	  16	  
0.7	  
61	  ±	  17	  
0.07	  
Comparison	  of	  CD38+	  cells	  percentage	  in	  cell	  cycle	  stages	  (S+G2/M	  and	  G0/G1)	  for	  samples	  frozen	  in	  
different	  cryopreservation	  media.	  P-­‐values	  compared	  the	  conventional	  with	  CryoStor	  media.	  Data	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Figure	  15:	  Proliferation	  potential	  of	  post-­‐thaw	  samples.	  
Percentage	  of	  CD38+	  cells	  at	  different	  cell	  cycle	  stages	  (S+G2/M	  and	  G0/G1)	  after	  48hrs	  in	  culture	  
post-­‐thaw.	  Data	  are	  presented	  as	  the	  mean	  ±	  SD.	  
Hypothermal	  storage	  
Red	  blood	  cell	  depleted	  CBU	  were	  suspended	  in	  Plasmalyte/HSA	  or	  Hypothermosol	  (HTS-­‐
FRS®	  media)	  and	  stored	  in	  a	  2-­‐8oC	  refrigerator.	  Samples	  were	  taken	  at	  24,	  48,	  and	  72hr	  for	  
analysis	  of	  cell	  subset	  viability,	  recovery,	  clonogenic	  capacity	  and	  proliferation	  ability.	  	  
Cell	  subset	  concentrations	  varied	  between	  CBU.	  For	  one	  of	  the	  CBU,	  CD90+	  and	  CD90-­‐	  
concentrations	  were	  very	  low	  (0.001	  %	  and	  0.02	  %).	  Because	  of	  that,	  that	  unit	  (CB-­‐4)	  was	  
excluded	  from	  the	  evaluation	  of	  these	  subsets.	  
Viability	  of	  progenitor	  cell	  subsets	  	  
The	  viability	  (%	  7-­‐AAD	  neg,	  Annexin-­‐V	  neg)	  of	  the	  various	  progenitor	  cell	  subsets	  after	  cold	  
storage	  in	  two	  different	  transport	  media	  is	  shown	  in	  Table	  10	  and	  Figure	  16.	  	  Viability	  of	  the	  
CD45+	  WBC	  population	  declined	  from	  an	  average	  of	  75%	  at	  time	  0	  to	  an	  average	  of	  62%	  
after	  72	  hrs	  in	  HTS-­‐FRS®	  media	  and	  to	  an	  average	  of	  34%	  after	  72	  hrs	  in	  Plasmalyte	  /HSA,	  
thus	  the	  viability	  declined	  to	  a	  significantly	  greater	  degree	  when	  stored	  in	  Plasmalyte	  /HSA	  
than	  when	  stored	  in	  HTS-­‐FRS®	  media	  (p-­‐value	  0.001).	  	  Similarly,	  the	  viability	  of	  the	  CD34+	  
cells	  declined	  more	  rapidly	  with	  storage	  in	  Plasmalyte/HSA,	  than	  they	  did	  during	  storage	  in	  




























other	  subsets	  analyzed	  either	  did	  not	  decline	  after	  72	  hrs,	  or	  the	  decline	  in	  viability	  was	  
comparable	  for	  both	  storage	  medias.	  	  
	  
Table	  10:	  Evaluation	  of	  cell	  subset	  viability	  in	  fresh	  and	  hypothermal	  stored	  samples.	  
	   	   CD90+	   CD90-­‐	   CD38-­‐	   CD38+	   CD34+	   WBC	   CD3+	  
Day	  0	  Fresh	   %Viable	   88	  ±	  8	   86	  ±	  5	   97	  ±	  3	   93	  ±	  3	   94	  ±	  3	   75	  ±	  9	   94	  ±	  5	  
Day	  1	  Plasma-­‐
Lyte	  A/HSA	   %Viable	   91	  ±	  0	   86	  ±	  0	  





95	  ±	  0	  
0.2	  
87	  ±	  0	  
0.3	  
90	  ±	  6	  
0.4	  
94	  ±	  3	  
0.9	  
93	  ±	  1	  
0.07	  
66	  ±	  2	  
1.0	  
93	  ±	  2	  
0.8	  
Day	  2	  Plasma-­‐





94	  ±	  1	  
0.4	  
93	  ±	  1	  
0.3	  
92	  ±	  3	  
0.6	  
92	  ±	  3	  
0.6	  
93	  ±	  1	  
0.3	  
60	  ±	  10	  
0.7	  
78	  ±	  17	  
0.2	  
Day	  3	  Plasma-­‐





91	  ±	  0	  
0.7	  
86	  ±	  0	  
0.8	  
96	  ±	  3	  
0.1	  
91	  ±	  2	  
0.5	  
94	  ±	  2	  
0.2	  
62	  ±	  13	  
0.008	  
88	  ±	  9	  
1.0	  
P-­‐values	  compare	  samples	  stored	  with	  conventional	  medium	  (Plasma-­‐Lyte	  A/0.5%HSA)	  or	  HTS-­‐















Figure	  16:	  Viability	  evaluation	  after	  hypothermal-­‐storage.	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Similarly,	  there	  was	  not	  a	  statistically	  significant	  difference	  in	  the	  percentage	  of	  cells	  
undergoing	  apoptosis	  after	  storage	  in	  either	  media,	  regardless	  of	  the	  cell	  subset	  analyzed	  
(Table	  11;	  Figure	  17).	  	  The	  percentage	  of	  cells	  undergoing	  apoptosis	  was	  highest	  in	  the	  
CD45+	  WBC	  population,	  most	  likely	  due	  to	  the	  death	  of	  granulocytes	  during	  storage,	  
however	  there	  was	  very	  little	  apoptosis	  occurring	  in	  any	  of	  the	  progenitor	  cell	  populations.	  	  	  
Table	  11:	  Apoptotic	  cell	  percentage	  in	  fresh	  and	  hypothermal-­‐stored	  samples.	  
	   	   CD90+	   CD90-­‐	   CD38-­‐	   CD38+	   CD34+	   WBC	   T	  CELL	  
Day	  0	  Fresh	   	  %Apo	   8	  ±	  5	   12	  ±	  5	   3	  ±	  3	   6	  ±	  5	   5	  ±	  4	   20	  ±	  8	   6	  ±	  5	  
Day	  1	  Plasma-­‐
Lyte	  A/HSA	   	  %Apo	   7	  ±	  0	   11	  ±	  0	   3	  ±	  1	   5	  ±	  3	   4	  ±	  1	   22	  ±	  1	   6	  ±	  7	  
Day	  1	  HTS-­‐FRS®	   	  %Apo	  P-­‐value	  
4	  ±	  0	  
0.3	  
9	  ±	  0	  
0.3	  
9	  ±	  5	  
0.3	  
5	  ±	  2	  
0.8	  
6	  ±	  1	  
0.5	  
23	  ±	  3	  
0.5	  
7	  ±	  2	  
0.9	  
Day	  2	  Plasma-­‐
Lyte	  A/HSA	   	  %Apo	   5	  ±	  0.5	   7	  ±	  1	   9	  ±	  9	   7	  ±	  3	   7	  ±	  4	   16	  ±	  3	   13	  ±	  7	  
Day	  2HTS-­‐FRS®	   	  %Apo	  P-­‐value	  
4	  ±	  0.3	  
0.2	  
4	  ±	  0	  
0.6	  
7	  ±	  3	  
0.7	  
6	  ±	  3	  
0.6	  
6	  ±	  1	  
0.4	  
19	  ±	  5	  
0.2	  
22	  ±	  17	  
0.5	  
Day	  3	  Plasma-­‐
Lyte	  A/HSA	   	  %Apo	   5	  ±	  0	   6	  ±	  0	   5	  ±	  5	   5	  ±	  4	   5	  ±	  4	   13	  ±	  15	   10	  ±	  12	  
Day	  3	  HTS-­‐FRS®	   	  %Apo	  P-­‐value	  
9	  ±	  0	  
0.6	  
8	  ±	  0	  
0.2	  
3	  ±	  3	  
0.7	  
7	  ±	  3	  
0.6	  
5	  ±	  2	  
0.8	  
15	  ±	  11	  
0.8	  
12	  ±	  9	  
0.9	  
P-­‐values	  compare	  samples	  stored	  with	  conventional	  medium	  (Plasma-­‐Lyte	  A/HSA)	  with	  others	  
stored	  with	  HTS-­‐FRS®	  medium	  processed	  on	  the	  same	  day.	  Data	  are	  presented	  as	  percentage	  mean	  
±	  SD.	  Day	  0,	  Day	  1	  and	  Day	  2	  (N=3);	  Day	  3	  (N=2).	  
	   	  









Figure	  17:	  Apoptotic	  populations	  after	  hypothermal-­‐storage.	  
Data	  are	  presented	  as	  percentage	  mean.	  Day	  0,	  Day	  1	  and	  Day	  2	  (N=3);	  Day	  3	  (N=2)	  
	  Post-­‐thaw	  TNC	  viable	  cell	  recovery	  varies	  between	  different	  cell	  subset.	  Variation	  between	  
hypothermal-­‐storage	  media	  was	  not	  statistically	  significant	  for	  HSC/P	  populations	  (CD90+,	  
CD90-­‐,	  CD38-­‐,	  CD38+	  and	  CD34+).	  On	  the	  other	  hand,	  variations	  in	  recovery	  of	  viable	  WBC	  
and	  CD3+	  after	  72	  h	  were	  statistically	  significant	  (p-­‐value	  0.001	  and	  0.01	  respectively).	  
Viable	  cell	  recovery	  increased	  for	  some	  cell	  subsets.	  Statistical	  study	  presented	  in	  Table	  12.	  
Figure	  18	  is	  a	  graphical	  representation	  of	  hypothermal	  stored	  cells	  recovery.	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Table	  12:	  Recovery	  of	  cell	  subsets	  after	  hypothermal	  storage.	  












113	  ±	  47	  
	  
0.7	  
102	  ±	  51	  
	  
0.9	  
94	  ±	  2	  
	  
0.2	  
151	  ±	  13	  
	  
0.4	  
137	  ±	  11	  
	  
1.0	  
88	  ±	  6	  
	  
0.7	  














144	  ±	  27	  
	  
0.6	  
102	  ±	  78	  
	  
0.6	  
196	  ±	  13	  
	  
0.5	  
127	  ±	  33	  
	  
0.7	  
148	  ±	  30	  
	  
0.9	  
66	  ±	  12	  
	  
0.4	  














182	  ±	  0	  
	  
0.3	  
110	  ±	  0	  
	  
0.7	  
148	  ±	  15	  
	  
0.1	  
161	  ±	  18	  
	  
0.4	  
146	  ±	  24	  
	  
1.0	  
48	  ±	  2	  
	  
0.001	  
49	  ±	  4	  
	  
0.01	  
P-­‐values	  compare	  samples	  stored	  with	  conventional	  medium	  (Plasma-­‐Lyte	  A/HSA)	  with	  others	  
stored	  with	  HTS-­‐FRS®	  medium	  processed	  on	  the	  same	  day.	  Data	  are	  expressed	  as	  percentage	  mean	  
±	  SD.	  
	   	  















Figure	  18:	  Cell	  subsets	  recovery	  after	  hypothermal	  storage.	  
Data	  are	  presented	  as	  percentage	  mean.	  Day	  0,	  Day	  1	  and	  Day	  2	  (N=3);	  Day	  3	  (N=2).	  
	  





















































Day1	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   Day	  3	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Recovery	  of	  ALDEFLUOR	  Bright	  cells	  
Recovery	  of	  CD45+	  CD34+,	  CD38-­‐	  ALDbr	  cells	  after	  storage	  for	  48	  or	  72	  hrs	  was	  significantly	  
improved	  when	  the	  cells	  were	  stored	  in	  HTS-­‐FRS®,	  compared	  to	  when	  the	  cells	  were	  stored	  
in	  Plasmalyte/HSA.	  	  (p-­‐values	  0.01	  and	  0.02X10-­‐3	  respectively).	  The	  difference	  was	  not	  
significant	  after	  24	  hrs,	  however	  (Table	  13;	  Figure	  19).	  	  
Table	  13:	  Recovery	  of	  ALDEFLUORbright	  cells	  after	  hypothermal-­‐storage.	  
	  	   %	  Recovery	  	  
Day	  1	  Plasma-­‐Lyte	  A/HSA	  	   137.4	  ±	  70	  
Day	  1	  HTS-­‐FRS®	  
P-­‐value	  
161.1	  ±	  81	  
0.2	  
Day	  2	  Plasma-­‐Lyte	  A/HSA	  	   123.4	  ±	  93	  




Day	  3	  Plasma-­‐Lyte	  A/HSA	  	   48.3	  ±	  35	  
Day	  3	  HTS-­‐FRS®	  
P-­‐value	  
197.6	  ±	  90	  
0.00002	  
P-­‐values	  compare	  samples	  stored	  with	  conventional	  medium	  (Plasma-­‐Lyte	  A/HSA)	  with	  others	  
stored	  with	  HTS-­‐FRS®	  medium	  processed	  on	  the	  same	  day.	  Data	  are	  presented	  as	  percentage	  mean	  
±	  SD.	  Day	  1	  and	  Day	  2	  (N=3);	  Day	  3	  (N=2).	  
	  
	  
Figure	  19:	  Recovery	  of	  ALDEFLUOR	  bright	  cells	  after	  hypothermal	  storage.	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Clonogenic	  capacity	  	  
Clonogenic	  capacity	  was	  evaluated	  after	  48	  and	  72	  h	  of	  refrigerated	  storage.	  	  The	  total	  
number	  of	  colonies	  that	  grew	  per	  105	  cells	  plated	  was	  reduced	  after	  48	  hrs	  (and	  72hrs)	  of	  
storage	  by	  approximately	  half	  (Table	  14),	  however	  there	  was	  not	  a	  statistically	  significant	  
difference	  in	  the	  recovery	  of	  clonogenic	  capacity	  between	  the	  2	  storage	  medias	  tested.	  	  The	  
same	  pattern	  occurred	  for	  the	  individual	  colony	  types	  (CFU-­‐GM;	  BFU-­‐E;	  CFU-­‐GEMM)	  as	  for	  
the	  total	  number	  of	  colonies	  that	  grew	  after	  storage	  (Table	  15).	  Also,	  the	  results	  were	  
similar	  for	  each	  individual	  cord	  blood	  tested	  (Figure	  20).	  	  	  
Table	  14:	  Clonogenic	  capacity	  after	  hypothermal-­‐storage.	  
	  













90	  ±	  37	   63	  ±	  41	  
	  
48	  ±	  26	  
0.6	  
40	  ±	  37	  
	  




95	  ±	  67	   66	  ±	  53	  
	  
49	  ±	  37	  
0.7	  
46	  ±	  51	  
	  




5	  ±	  1	   1	  ±	  0	   2	  ±	  2	  
0.6	  




190	  ±	  104	   130	  ±	  94	  
	  
99	  ±	  61	  
0.6	  
87	  ±	  88	  
	  
79	  ±	  77	  
0.9	  
Number	  of	  colonies	  /105	  plated	  cells	  presented	  as	  mean	  ±	  SD	  (N=3)	  	  
	  
Table	  15:	  Recovery	  of	  CFU	  	  










BFU-­‐E	  recovery	  %	  
P-­‐value	  






CFU-­‐GM	  recovery	  %	  
P-­‐value	  


























Recovery	  of	  CFU	  in	  hypothermal	  stored	  samples.	  P-­‐value	  calculated	  comparing	  the	  recovery	  of	  
samples	  stored	  with	  Plasma-­‐Lyte	  A/0.5	  %	  HSA	  vs.	  HTS-­‐FRS®	  (N=3).	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Figure	  20:	  Clonogenic	  capacity	  after	  hypothermal	  storage.	  
(A)	  Total	  number	  of	  formed	  colonies	  /105	  plated	  cells	  for	  each	  unit.	  (B)	  Mean	  of	  the	  total	  number	  of	  
formed	  colonies	  /105	  from	  the	  three	  samples.	  	  
Proliferation	  capacity	  
The	  ability	  of	  the	  CD34+,	  CD38-­‐	  progenitor	  cells	  within	  the	  cord	  blood	  samples	  to	  proliferate	  
in	  culture	  in	  response	  to	  cytokine	  stimulation	  was	  tested	  after	  48	  and	  72	  h	  of	  refrigerated	  
storage	  using	  the	  same	  procedures	  followed	  for	  post-­‐thaw	  samples.	  A	  slightly	  larger	  
percentage	  of	  the	  cells	  were	  able	  to	  proliferate	  in	  culture	  after	  storage	  in	  HTS-­‐FRS®	  	  	  
compared	  to	  Plasmalyte/HSA,	  however	  this	  difference	  was	  not	  statistically	  significant	  (p-­‐
value	  0.5	  -­‐	  0.9)	  (Table	  16;	  Figure	  21-­‐A	  and	  B).	  	  Interestingly,	  comparing	  the	  results	  shown	  in	  
Table	  16	  with	  those	  shown	  in	  Table	  9,	  a	  larger	  percentage	  of	  the	  cells	  were	  able	  to	  
proliferate	  in	  culture	  (higher	  G2+M	  percentage)	  after	  the	  cells	  were	  cryopreserved	  and	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  Plasmalyte/HSA	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  HTS-­‐FRS®	  	  	  
DAY3	  Plasmalyte/HSA	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Table	  16:	  Proliferation	  potential	  after	  hypothermal-­‐storage.	  
	   S+G2/M	   G0/G1	  
Day	  2	  Plasma-­‐Lyte	  A/HSA	  	   12.1	  ±	  6	   13.5	  ±	  10	  
Day	  2	  HTS-­‐FRS®	  
P-­‐value	  
17.2	  ±	  2	  
0.8	  
11.1	  ±	  5	  
0.9	  
Day	  3	  Plasma-­‐Lyte	  A/HSA	  	   17.3	  ±	  3	   9.1	  ±	  6	  
Day	  3	  HTS-­‐FRS®	  
P-­‐value	  
20.3	  ±	  9	  
0.5	  
9.1	  ±	  4	  
1.0	  
Comparison	  of	  CD38-­‐	  cells	  percentage	  in	  proliferative	  staged	  (S+G2/M),	  quiescent	  stages	  (G0/G1)	  for	  
samples	  stored	  at	  different	  hypothermal	  storage	  media.	  Data	  are	  presented	  as	  percentage	  mean	  ±	  
SD	  (N=3).	  
A	   B	  
	   	  
	  	  	  
Figure	  21:	  BrdU	  incorporation	  assay	  evaluation	  after	  hypothermal-­‐storage.	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DISCUSSION	  
In	  this	  study,	  a	  comparison	  was	  made	  between	  commercially	  available	  serum	  free	  
cryopreservation	  solutions	  (CryoStor®)	  that	  contain	  either	  5	  %	  or	  10	  %	  DMSO	  with	  
Hoxworth	  Blood	  Center’s	  conventional	  formulation,	  containing	  5	  %	  DMSO,	  2.5	  %	  HES,	  10	  %	  
ACD-­‐A	  and	  10	  %	  HSA.	  Comparison	  was	  based	  on	  post-­‐thaw	  viability	  and	  recovery	  of	  viable	  
cell	  subsets	  (CD90+,	  CD90-­‐,	  ALDbr,	  CD38-­‐,	  CD38+,	  CD34+,	  WBC	  and	  CD3+),	  clonogenic	  
capacity,	  and	  proliferation	  potential.	  The	  results	  showed	  a	  variation	  in	  cell	  viability	  and	  
viable	  cell	  recovery	  between	  different	  cell	  subsets	  in	  different	  cryopreservation	  media.	  
Recovery	  of	  progenitor	  cells	  subsets	  (CD38-­‐,	  CD38+,	  and	  CD34+)	  was	  better	  than	  it	  for	  the	  
overall	  recovery	  of	  WBC	  (CD45+),	  which	  is	  consistent	  with	  previous	  findings	  that	  CD34+	  cells	  
are	  more	  resistant	  to	  cryopreservation	  than	  other	  mononuclear	  cells,	  perhaps	  because	  of	  
their	  quiescent	  nature	  or	  because	  of	  the	  nature	  of	  their	  membrane	  lipid	  and	  protein	  
content.37-­‐39	  	  The	  concentration	  of	  CD3+	  cells	  was	  low	  in	  fresh	  CBU	  (23	  %)	  and	  it	  decreased	  
sharply	  in	  post-­‐thaw	  samples	  (10,	  7	  and	  13	  %	  in	  conventional,	  CS5,	  and	  CS10	  respectively).	  
That	  decrease	  resulted	  in	  a	  poor	  recovery	  of	  the	  CD3+	  population	  (37±9	  %,	  27	  ±	  15	  %	  and	  51	  
±	  10	  %	  in	  conventional,	  CS5,	  and	  CS10	  respectively).	  Stroncek	  et	  al.	  evaluated	  CD3+	  recovery	  
in	  post-­‐thaw	  WBC	  collected	  from	  HSC	  transplant	  donors	  (N=311);	  recovery	  of	  CD3+	  was	  76	  ±	  
16	  %.40	  On	  the	  other	  hand,	  viability	  of	  WBC	  decreased	  sharply	  in	  post-­‐thaw	  samples	  
resulting	  in	  a	  poor	  recovery	  of	  viable	  WBC	  with	  all	  cryopreservation	  media.	  That	  decrease	  
might	  be	  caused	  by	  the	  loss	  of	  granulocytes	  in	  post-­‐thaw	  samples	  (Figure	  22).	  Evaluation	  of	  
the	  total	  WBC	  viability	  was	  included	  in	  the	  study	  to	  emphasize	  differences	  between	  storage	  
media,	  despite	  the	  fact	  that	  loss	  of	  the	  mature	  granulocyte	  will	  not	  affect	  the	  quality	  of	  HSC	  
products	  because	  these	  cells	  don’t	  play	  a	  role	  in	  short	  or	  long	  term	  engraftment.	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Figure	  22:	  Loss	  of	  granulocytes	  in	  post-­‐thaw	  samples.	  
Flow	  cytometry	  light	  scatter	  plots	  show	  a	  significant	  loss	  of	  the	  granulocyte	  population	  in	  post-­‐thaw	  
samples.	  FSC-­‐A	  =	  forward	  scatter	  area.	  SSC-­‐A	  =	  side	  scatter	  area.	  
Other	  cell	  HSC/P	  subsets	  were	  not	  included	  in	  a	  comparison	  of	  cryopreservation	  media	  in	  
previous	  studies.	  In	  comparing	  cryopreservation	  media,	  there	  were	  no	  significant	  
differences	  in	  the	  viability	  or	  recovery	  of	  all	  cell	  subsets.	  Results	  showed	  a	  slight	  variation	  in	  
clonogenic	  capacity	  and	  proliferation	  potential	  between	  samples	  stored	  with	  different	  
cryopreservation	  solutions	  with	  preferable	  results	  for	  cells	  cryopreserved	  with	  CS10.	  There	  
was	  a	  strong	  positive	  correlation	  between	  proliferative	  cells	  and	  CFU	  in	  CB1	  and	  CB-­‐2	  (R=1)	  
and	  negative	  correlation	  with	  CB-­‐3	  (R=-­‐0.9).	  	  
Variation	  between	  cryopreservation	  media	  in	  viability,	  recovery	  of	  viable	  cell	  subsets	  and	  in-­‐
vitro	  functional	  assays	  were	  not	  statistically	  significant.	  	  
Other	  studies	  have	  been	  performed	  in	  the	  past	  to	  evaluate	  the	  effect	  of	  different	  DMSO	  
concentrations	  on	  cryopreservation	  of	  HSC.	  	  Liseth	  et	  al.	  used	  PBPC-­‐derived	  stem	  cells	  to	  
determine	  the	  differences	  in	  viability	  (7-­‐AAD	  only)	  of	  CD34+	  and	  WBC	  in	  post-­‐thaw	  samples	  
using	  different	  DMSO	  concentrations.	  	  DMSO	  was	  added	  directly	  to	  HSC	  suspension	  (with	  
autologous	  plasma).	  This	  study	  concluded	  that	  cell	  concentration	  at	  cryopreservation	  had	  an	  
effect	  on	  the	  post-­‐thaw	  result	  and	  that	  5	  %	  DMSO	  is	  the	  optimal	  concentration	  for	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cryopreserving	  PBPC,	  if	  the	  cell	  concentration	  did	  not	  exceed	  200	  X	  106	  NC/mL.41	  	  	  Variation	  
in	  the	  duration	  of	  liquid	  nitrogen	  storage	  proved	  to	  have	  no	  effect	  on	  the	  recovery	  or	  
viability	  post-­‐thaw,	  however	  the	  procedures	  for	  cryopreservation,	  thawing,	  cell	  subset	  
identification,	  viability	  evaluation	  and	  timing	  before	  testing	  differed	  from	  our	  study,	  making	  
comparisons	  difficult.	  	  
Abrahamsen	  et	  al.	  also	  used	  PBPC	  derived	  stem	  cells	  to	  compare	  viability	  (7-­‐AAD	  and	  
annexin-­‐V)	  of	  post-­‐thawed	  samples	  stored	  in	  5	  %	  or	  10	  %	  DMS0.	  They	  followed	  the	  same	  
cryopreservation	  procedure	  that	  Liseth	  et	  al.	  used.	  Their	  results	  indicated	  that	  5	  %	  DMSO	  
resulted	  in	  better	  viability	  and	  recovery	  of	  CD34+	  cells.	  Furthermore,	  5	  %	  DMSO	  resulted	  in	  
less	  Apoptosis	  (7-­‐AAD	  neg.;	  annexin-­‐V	  pos.)	  and	  necrosis	  (7-­‐AAD	  pos.;	  annexin-­‐V	  pos.	  or	  
neg.),	  however	  their	  cryopreservation	  evaluation	  did	  not	  include	  any	  functional	  
measurement	  of	  the	  recovered	  post-­‐thaw	  cells.	  42	  
Other	  studies	  comparing	  the	  commercially	  available	  CryoStor	  media	  with	  other	  lab-­‐
formulated	  media	  concluded	  different	  findings.	  Clarke	  et	  al.	  used	  peripheral	  blood	  HSC/P	  
cells	  at	  50	  X	  106/mL	  to	  compare	  CS5,	  CS10	  and	  a	  conventional	  media	  formulation	  used	  at	  
Fred	  Hutchinson	  Cancer	  Research	  Center	  (FHCRC)	  that	  contains	  Normosol-­‐R,	  5	  %	  HSA	  and	  10	  
%	  DMSO.	  Cryopreservation	  media	  were	  added	  in	  1:	  1	  dilution	  then	  samples	  were	  thawed	  
and	  diluted	  to	  1:32	  in	  TM	  containing	  D-­‐PBS	  and	  11	  %	  FBS.	  Evaluation	  was	  based	  on	  recovery	  
and	  viability	  of	  TNC,	  CD34+	  and	  granulocytes	  (using	  7-­‐AAD	  only),	  and	  CFU	  (N=9).	  Results	  
revealed	  that	  samples	  stored	  in	  CS10	  yielded	  a	  significant	  increase	  in	  recovery	  of	  viable	  
CD34+	  and	  CFU.	  43	  Another	  study	  by	  Stylianou	  et	  al.	  used	  CB	  derived	  HSC	  to	  compare	  CS5,	  
CS10	  with	  10	  %	  DMSO	  in	  dextran-­‐40.	  Evaluation	  was	  based	  on	  TNC,	  CFU	  and	  recovery	  and	  
viability	  of	  CD34+	  (using	  annexin-­‐V	  and	  7-­‐AAD)	  (N=30).	  Units	  were	  thawed	  and	  mixed	  for	  2	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min.	  before	  testing.	  Post-­‐thaw	  results	  from	  samples	  stored	  with	  CS10	  showed	  an	  
improvement	  in	  TNC	  recovery,	  clonogenic	  capacity	  and	  CD34+	  recovery	  and	  viability.	  
Improvement	  in	  CD34+	  recovery	  and	  viability	  was	  not	  statistically	  significant	  with	  CS5.	  31	  	  
These	  findings	  are	  similar	  to	  our	  results;	  the	  samples	  cryopreserved	  with	  CS10	  showed	  a	  
trend	  to	  produce	  more	  colonies	  but	  it	  was	  not	  statistically	  significant	  (p-­‐value	  0.6	  for	  the	  
total	  number	  of	  formed	  colonies/105	  plated	  cells).	  
Comparing	  the	  conventional	  and	  HTS-­‐FRS®	  showed	  similar	  viability,	  viable	  cell	  and	  ALDbr	  
recovery	  results	  after	  24	  h	  (day	  1)	  and	  the	  variation	  increases	  after	  24	  h	  of	  storage	  with	  a	  
preferable	  viability,	  viable	  cell	  recovery	  and	  proliferation	  capacity	  from	  samples	  stored	  with	  
HTS-­‐FRS®.	  That	  variation	  was	  statistically	  significant	  for	  viable	  WBC	  at	  day	  3,	  recovery	  of	  
viable	  WBC	  and	  CD3+	  at	  Day	  3	  and	  recovery	  of	  ALDbr	  at	  day	  2	  and	  3,	  with	  superior	  results	  
from	  samples	  stored	  in	  HTS-­‐FRS®.	  Furthermore,	  an	  increase	  in	  the	  viability	  of	  the	  CD38-­‐	  
population	  from	  samples	  stored	  in	  HTS-­‐FRS®	  was	  associated	  with	  an	  increase	  in	  the	  ALDbr	  
recovery	  and	  an	  increase	  in	  the	  recovery	  of	  viable	  CD38+	  was	  associated	  with	  an	  increase	  in	  
the	  proliferation	  potential.	  The	  clonogenic	  capacity	  decreased	  in	  hypothermal	  stored	  
samples	  with	  both	  media	  with	  better	  recovery	  for	  samples	  stored	  with	  Plasma-­‐Lyte	  A/0.5	  
HSA.	  
Mathew	  et	  al.	  have	  shown	  that	  storing	  different	  kinds	  of	  tissues	  in	  HTS-­‐FRS®	  at	  4°C	  improves	  
post-­‐storage	  viability	  and	  functionality.	  They	  also	  suggested	  that	  preservation	  solutions	  
should	  be	  designed	  to	  meet	  the	  unique	  molecular	  and	  biological	  requirements	  for	  each	  cell	  
type.	  29	  A	  better	  understanding	  of	  the	  molecular	  biology	  of	  HSC	  apoptosis	  could	  lead	  to	  
improved	  storage	  by	  modifying	  the	  ingredients	  of	  the	  HTS-­‐FRS®	  to	  reduce	  cell	  loss.	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Correlation	  between	  the	  viable	  HSC/P	  cell	  subsets	  (CD90+,	  CD90-­‐,	  CD38-­‐,	  ALDbr,	  CD38+	  and	  
CD34+)	  and	  the	  CFU	  and	  proliferation	  (G2/M	  stage)	  data	  was	  not	  possible.	  That	  necessitates	  
an	  in-­‐vivo	  study	  to	  know	  the	  effect	  of	  viability	  percentage	  of	  HSC/P	  subset	  in	  its	  
functionality	  (engraftment	  outcomes).	  	  
Commercially	  available	  media	  CryoStor®	  and	  HTS-­‐FRS®	  contain	  similar	  components	  except	  
for	  the	  DMSO.	  	  HTS-­‐FRS®	  contains	  more	  nutrition	  which	  provides	  stored	  cells	  with	  the	  
required	  support	  when	  its	  metabolic	  activities	  are	  reduced	  and	  more	  pH	  stabilizer	  to	  
overcome	  changes	  in	  the	  pH	  during	  storage.	  The	  HTS-­‐FRS®	  has	  an	  advantage	  over	  the	  
Plasma-­‐Lyte	  A/0.5%	  HSA	  as	  it	  provides	  more	  nutrition,	  better	  pH	  control,	  free	  radical	  
scavengers.	  Perhaps	  an	  improvement	  in	  the	  conventional	  hypothermal	  storage	  media	  
(Plasma-­‐Lyte	  A/0.5%	  HSA)	  could	  be	  achieved	  by	  increasing	  the	  albumin	  concentration	  (2	  
g/dL)	  to	  mimic	  its	  normal	  physiological	  levels	  in	  the	  plasma	  (3.4-­‐5.4	  g/dL).	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CONCLUSIONS	  
Our	  results	  indicate	  that	  cell	  subsets	  differ	  in	  their	  resistance	  to	  cryopreservation	  injury,	  as	  
indicated	  by	  differences	  in	  	  post-­‐thaw	  viability	  measurements.	  Comparing	  the	  conventional	  
cryopreservation	  medium	  with	  CS5	  and	  CS10	  showed	  no	  statistically	  significant	  difference	  
between	  the	  groups,	  but	  with	  a	  trend	  toward	  improvement	  in	  clonogenic	  capacity	  and	  
proliferation	  potential	  with	  CS10.	  	  Further	  evaluation	  with	  more	  samples	  is	  required	  to	  
support	  the	  benefits	  of	  CS10	  over	  the	  conventional	  media.	  In	  general,	  as	  the	  low	  
concentration	  of	  DMSO	  reduces	  the	  	  DMSO	  toxicity	  upon	  transfusion,	  and	  the	  variation	  
between	  conventional	  and	  CS5	  was	  not	  statistically	  significant,	  the	  conventional	  medium	  is	  
equally	  effective	  in	  cryopreservation	  of	  HSC	  products.	  
The	  hypothermal	  storage	  study	  proved	  that	  the	  conventional	  (Plasma-­‐Lyte	  A/0.5	  %HSA)	  
medium	  is	  suitable	  for	  holding	  HSC	  products	  for	  24	  h,	  but	  not	  for	  transporting	  fresh	  
products	  if	  the	  transport	  duration	  will	  be	  more	  than	  24	  h	  
Using	  the	  commercially	  available	  CryoStor®	  or	  HTS-­‐FRS®	  media	  rather	  than	  preparing	  it	  in	  
the	  lab	  is	  beneficial	  as	  it	  will	  standardize	  the	  cryopreservation	  procedures	  and	  reduce	  errors	  
in	  processing	  cellular	  therapy	  products	  caused	  by	  the	  multistep	  conventional	  processes.	  
Increasing	  the	  sample	  size,	  	  including	  other	  cell	  types,	  and	  performing	  in-­‐vivo	  analyses	  might	  
enable	  the	  detection	  of	  minor	  differences	  in	  these	  storage	  media.	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